<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">106657</article-id><article-id pub-id-type="doi">10.7554/eLife.106657</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.106657.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Conserved and unique features of terminal telomeric sequences in ALT-positive cancer cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Azeroglu</surname><given-names>Benura</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7243-384X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Pavani</surname><given-names>Raphael</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7187-2995</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sandhu</surname><given-names>Ranjodh Singh</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0008-2340-3423</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>Tadahiko</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Nussenzweig</surname><given-names>André</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lazzerini-Denchi</surname><given-names>Eros</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5378-4644</contrib-id><email>eros.lazzerinidenchi@nih.gov</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040gcmg81</institution-id><institution>Laboratory of Genome Integrity, National Cancer Institute, National Institutes of Health</institution></institution-wrap><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Cooper</surname><given-names>Julia Promisel</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wmf1y16</institution-id><institution>University of Colorado Anschutz Medical Campus</institution></institution-wrap><addr-line><named-content content-type="city">Aurora</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Marston</surname><given-names>Adèle L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Kyoto University, Kyoto, Japan</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>08</month><year>2025</year></pub-date><volume>14</volume><elocation-id>RP106657</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2025-03-08"><day>08</day><month>03</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2025-03-02"><day>02</day><month>03</month><year>2025</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2025.02.27.640565"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-12"><day>12</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106657.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-07-17"><day>17</day><month>07</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.106657.2"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-106657-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-106657-figures-v1.pdf"/><abstract><p>A significant portion of human cancers utilize a recombination-based pathway, alternative lengthening of telomeres (ALT), to maintain telomere length. Targeting the ALT is of growing interest as a cancer therapy, yet a substantial knowledge gap remains regarding the basic features of telomeres in ALT-positive cells. To address this, we adopted END-seq, an unbiased sequencing-based approach, to define the identity and regulation of the terminal sequences of chromosomes in ALT cells. Our data reveal that the terminal portions of chromosomes in ALT cells contain canonical telomeric sequences with the same terminus bias (-ATC) observed in non-ALT cells. Furthermore, as reported for non-ALT cells, POT1 is required to preserve the precise regulation of the 5′ end in cells that maintain telomere length using the ALT pathway. Thus, the regulation of the terminal 5′ of chromosomes occurs independently of the mechanism of telomere elongation. Additionally, we employed an S1 endonuclease-based sequencing method to determine the presence and origin of single-stranded regions within ALT telomeres. These data shed light on conserved and unique features of ALT telomeres.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>ALT</kwd><kwd>telomeres</kwd><kwd>ssDNA</kwd><kwd>END-seq</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Other</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1-ZIA-BC011815-03</award-id><principal-award-recipient><name><surname>Lazzerini-Denchi</surname><given-names>Eros</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Abundant single-stranded telomeric DNA distinguishes alternative lengthening of telomeres-positive cells and represents a potential biomarker and therapeutic vulnerability.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Telomeres are the natural ends of eukaryotic chromosomes and are critical for maintaining chromosome integrity (<xref ref-type="bibr" rid="bib43">Palm and de Lange, 2008</xref>). Human telomeres consist of 5–15 kilobases of repetitive DNA sequences (5′-<named-content content-type="sequence">TTAGGG</named-content>-3′), which serve as a binding platform for an essential protective protein complex named shelterin (<xref ref-type="bibr" rid="bib43">Palm and de Lange, 2008</xref>). The terminal portion of chromosomes is composed of a single-stranded 3′ overhang of approximately 200 nucleotides, generated by the interplay between DNA replication and end-processing, and regulated by the telomere-associated protein POT1 (<xref ref-type="bibr" rid="bib8">Cai and de Lange, 2023</xref>; <xref ref-type="bibr" rid="bib31">Lim and Cech, 2021</xref>). It is noteworthy that the generation of the 3′ overhang differs between leading and lagging strand telomeres. At leading strand telomeres, the newly synthesized DNA terminates in a blunt end and requires post-replicative resection by nucleases such as Apollo and Exo1 and a fill-in action promoted by CST complex to create the 5′ overhang (<xref ref-type="bibr" rid="bib58">Wu et al., 2012</xref>). In contrast, lagging strand synthesis inherently generates a 3′ overhang due to Okazaki fragment processing, where removal of the terminal RNA primer leaves a single-stranded gap that is partially filled in by DNA polymerase α-primase with the aid of the CST complex (<xref ref-type="bibr" rid="bib55">Takai et al., 2024</xref>; for reviews, see <xref ref-type="bibr" rid="bib8">Cai and de Lange, 2023</xref>; <xref ref-type="bibr" rid="bib31">Lim and Cech, 2021</xref>). Progressive loss of telomeric repeats during DNA replication leads to telomere shortening and represents a barrier to unlimited proliferation (<xref ref-type="bibr" rid="bib19">Feldser and Greider, 2007</xref>; <xref ref-type="bibr" rid="bib21">Greenberg et al., 1998</xref>; <xref ref-type="bibr" rid="bib22">Greider, 1996</xref>; <xref ref-type="bibr" rid="bib46">Perera et al., 2008</xref>). To overcome this tumor suppressive barrier, ~85% of cancers activate telomerase, a reverse transcriptase, to synthesize new telomeric repeats (<xref ref-type="bibr" rid="bib50">Shay and Bacchetti, 1997</xref>; <xref ref-type="bibr" rid="bib30">Kim et al., 1994</xref>). The remaining ~15% of cancers engage the alternative lengthening of telomeres (ALT) pathway, a recombination-based mechanism to elongate telomeres using existing telomeric DNA as a template (<xref ref-type="bibr" rid="bib18">Dunham et al., 2000</xref>; <xref ref-type="bibr" rid="bib7">Bryan et al., 1997</xref>). Major advancements in our understanding of the ALT pathway at the molecular level have been made over recent years, shedding light on the molecular pathways involved in telomere elongation as well as the genetic vulnerabilities of ALT-positive cells (<xref ref-type="bibr" rid="bib28">Jiang et al., 2024</xref>; <xref ref-type="bibr" rid="bib34">Lu et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Pan et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Panier et al., 2019</xref>; <xref ref-type="bibr" rid="bib51">Silva et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Dilley et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Barroso-González et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Kaminski et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Lynskey et al., 2024</xref>; <xref ref-type="bibr" rid="bib3">Azeroglu et al., 2025</xref>; for reviews, see <xref ref-type="bibr" rid="bib6">Bhargava et al., 2022</xref>; <xref ref-type="bibr" rid="bib12">Claude and Decottignies, 2020</xref>; <xref ref-type="bibr" rid="bib33">Loe et al., 2023</xref>; <xref ref-type="bibr" rid="bib42">O’Sullivan and Greenberg, 2025</xref>).</p><p>Due to the repetitive nature of telomeres, some fundamental questions about the composition of ALT telomeres remain unanswered. Specifically, it is unclear if 5′ telomere ends in ALT cells differ from telomerase-positive cells, whether they follow the same rules for end protection, and whether ALT telomeres contain any unique secondary structures. It is foreseeable that telomeres in telomerase-positive cells and ALT cells differ, as ALT can generate complex and non-canonical telomeric sequences, and secondary structures through recombination-based mechanisms. Interestingly, positive staining for the single-strand binding protein RPA and native FISH staining (ssTelo) of telomeres suggested the presence of single-stranded DNA regions in ALT-positive cells (<xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Grudic et al., 2007</xref>). However, the source or extent of ssDNA in ALT telomeres remains unclear. Intriguingly, EM data and rolling-circle amplification-based assays suggest that ALT frequently contain circular extrachromosomal telomeric DNA termed C-circles (<xref ref-type="bibr" rid="bib25">Henson et al., 2009</xref>; <xref ref-type="bibr" rid="bib10">Cesare and Griffith, 2004</xref>).</p><p>Here, we report a novel approach to studying ALT telomeres using the high-resolution and unbiased method known as END-seq (<xref ref-type="bibr" rid="bib9">Canela et al., 2016</xref>). Using this method, we find that the terminal sequence of ALT chromosomes consists of canonical telomeric repeats, shares the same bias in the 5′ terminus as telomeres maintained by telomerase, and terminates with ATC-5′. Furthermore, we demonstrated that this bias is influenced by the shelterin component, POT1.</p><p>Secondly, to assess the presence of ssDNA at ALT telomeres, we used S1 nuclease, an enzyme that specifically degrades single-stranded DNA including the single-stranded regions in duplex DNA. Using S1 nuclease treatment coupled with END-seq (S1-END-seq) (<xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref>), we show that ALT telomeres have tracts of ssDNA and the presence of ssDNA in telomeres can be used to distinguish ALT-positive from ALT-negative cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>END-seq efficiently captures 5′ chromosome termini</title><p>To study the terminal portion of chromosome, we employed an unbiased and high-resolution approach developed to map and investigate double-strand breaks (DSBs): END-seq (<xref ref-type="bibr" rid="bib9">Canela et al., 2016</xref>). In this method, biotin-labeled adaptors are ligated to DSBs, which enable their purification and subsequent sequencing by next-generation sequencing (NGS). Based on the directionality of DNA sequencing (5′ to 3′), DSBs are identified as unidirectional reads that originate from the lesion site on either side of the break (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Chromosome ends resemble one-ended DSBs, which by END-seq should be detected as unidirectional reads corresponding to the 5′ telomeric strand, the C-rich strand. To test this hypothesis, we performed END-seq on two telomerase-positive human cell lines, HeLa and telomerase-expressing RPE1. Sequencing reads containing four consecutive <named-content content-type="sequence">TTAGGG</named-content> repeats (G-rich) or <named-content content-type="sequence">CCCTAA</named-content> repeats (C-rich) were defined as “telomeric reads” and were normalized to the total number of reads obtained in each individual library. Strikingly, virtually all (99.9%) telomeric END-seq reads correspond to the C-rich strand, in agreement with the fact that chromosome ends are one-ended DSBs (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). To exclude possible artifacts derived from the repetitive nature of telomeric reads, we performed a similar analysis of reads corresponding to pan-centromeric repeats; this analysis shows that although the fraction of their presence in the human genome was similar (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), the pan-centromeric sequences are not enriched to the same level as telomeres nor show any strand bias when detected (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>END-seq successfully captures the 5′ termini of human and mouse chromosomes.</title><p>(<bold>A</bold>) Schematic representation of the END-seq method applied to double-strand breaks (DSBs) (left) and natural chromosome ends (right). Blunted dsDNA ends are ligated to biotinylated adaptors, purified, and subsequently sequenced by next-generation sequencing (NGS). Reads originating from DSBs align to either side of the break (left), while telomeric reads align only to the 5′ C-rich template (red). (<bold>B</bold>) Number of reads containing at least four consecutive telomeric repeats corresponding to the G-rich (green) and C-rich (red) strands in HeLa and RPE1 cell lines. Telomeric reads are normalized to the total number of reads identified by END-seq and are represented as reads per million (RPM). (<bold>C</bold>) Sequence logo representing the conservation (bits) of the last 6 nucleotides at the 5′ end of chromosomes in HeLa and RPE1 cells. (<bold>D</bold>) Distribution of the three most frequent telomeric repeats across human cell lines (orange), mouse cells (yellow), and a canine cell line (purple). (<bold>E</bold>) Schematic representation of T7-mediated randomization of the 5′ termini. (<bold>F</bold>) Percentage of telomeric reads that have the indicated sequence as a 5′ end. The following sequences (<named-content content-type="sequence">CCCAAT</named-content>-5′, <named-content content-type="sequence">TCCCAA</named-content>-5′, and <named-content content-type="sequence">ATCCCA</named-content>-5′) are grouped and labeled as ‘Rest’. Kullback–Leibler divergence (KL divergence) analysis was used to compare the distributions of the individual conditions. KL divergence between 0.25 and 0.375 is represented by two dots. Prior to the END-seq protocol, cells were either left untreated (NT) or were treated with T7. (<bold>G</bold>) Percentage of telomeric reads is displayed as described in (<bold>F</bold>). Cells expressing either a nontargeting shRNA (shScr) or an shRNA targeting POT1 (shPOT1) were harvested 3 days post induction and analyzed by END-seq. KL divergence between 0.125 and 0.25 is represented by one dot (●).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Analysis of telomeric and centromeric reads and 5′ termini randomization.</title><p>(<bold>A</bold>) Relative abundance of pan-centromeric and telomeric reads. Reads per million (RPM) of pan-centromeric and telomeric reads found in the human T2T reference genome (<xref ref-type="bibr" rid="bib39">Nurk et al., 2022</xref>). (<bold>B</bold>) Normalized number of pan-centromeric and telomeric reads aligned to Watson and Crick strands in HeLa and RPE1-hTERT cell lines. For telomeres, three units of <named-content content-type="sequence">TTAGGG</named-content> or <named-content content-type="sequence">CCCTAA</named-content> were used to call Watson (green) or Crick (red) strands. For centromeres, one unit of <named-content content-type="sequence">AAACTAGACAGAAGCATT</named-content> or <named-content content-type="sequence">AATGCTTCTGTCTAGTTT</named-content> was used to call Watson (green) or Crick (red) strands. (<bold>C</bold>) Sequence logo representing the conservation (bits) of the 5′ termini with absolute randomization (top) versus absolute precision (bottom). (<bold>D</bold>) Effect of in vitro randomization of 5′ termini by T7 exonuclease. Replotting of data presented in <xref ref-type="fig" rid="fig1">Figure 1F</xref>. Percentage of telomeric reads that have the indicated sequence as a 5′ sequence that have as a 5′ end. (<bold>E</bold>, <bold>F</bold>) Comparison of experimental data with modeled predictions to assess the impact of varying degrees of randomization on the <named-content content-type="sequence">CCAATC</named-content>-5′ termini. The data presented in <xref ref-type="fig" rid="fig1">Figure 1F</xref> for in-plug treatment of T7 (<bold>E</bold>) and in <xref ref-type="fig" rid="fig1">Figure 1G</xref> for POT1 depletion (<bold>F</bold>) show varying degrees of randomization compared to their respective untreated controls. (<bold>G</bold>) Relative expression level of POT1 in HeLa cells expression inducible shRNA against POT1 (shPOT1) compared to control (shScr) after 3 days of shRNA induction by doxycycline.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Next, we performed a motif analysis on the C-rich telomeric END-seq reads to determine the prevalent terminal chromosomal sequence. This analysis shows that the vast majority (78% and 65% for HeLa and RPE1, respectively) of chromosomes end with ATC-5′ (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>). Strikingly, this is in agreement with previous data obtained using a PCR-based approach termed STELA on defined chromosome ends in HeLa cells (<xref ref-type="bibr" rid="bib48">Sfeir et al., 2005</xref>). A major advantage of END-seq over STELA is that it can be applied to telomeres of any length and chromosome location without the need of specific sub-telomeric primers. This excludes possible biases and allows the analysis of telomeres from any cell type and origin. As proof of principle, we expanded the analysis to a collection of telomerase-positive human cell lines, as well as mouse and dog cell lines, and mouse tissues. In these experiments, we found that chromosome ends show a strong bias for ATC-5′ as a terminal sequencing (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), in line with previous findings (<xref ref-type="bibr" rid="bib56">Tesmer et al., 2023</xref>; <xref ref-type="bibr" rid="bib52">Smoom et al., 2023</xref>), suggesting a conserved mechanism for its generation.</p><p>To further validate END-seq as a method to identify terminal telomeric repeats, we tested whether 5′–3′ T7 exonuclease treatment prior to END-seq would be sufficient to change the bias of the ATC-5′ sequence (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Since T7 exonuclease preferentially degrades 5′ ends of double-stranded DNA while leaving 3′ single-stranded overhangs intact, we expected that its treatment would randomize the 5′ telomeric ends by progressively resecting them, thereby disrupting the original sequence bias. If END-seq was biased or not sufficiently sensitive, T7 treatment would not significantly alter the detected sequence distribution. As shown in <xref ref-type="fig" rid="fig1">Figure 1F</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>, T7-treated samples display an altered distribution of telomeric permutations. Quantitative measurement of the difference in distribution of possible telomeric permutations in the presence or absence of T7 treatment was performed using the Kullback–Leibler divergence (KL divergence) score. The result of this analysis indicated that the samples are extremely divergent (●● indicates a KL divergence value between 0.375 and 0.5). To further evaluate the distribution changes between these conditions, we compared the reads obtained from these samples with <italic>in silico</italic>-generated control reads representing various degrees of randomization from the ATC-5′ sequences (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D and E</xref>). Using the KL divergence score, we determined that T7-randomized samples were most similar to a population where 100% of the reads were equally randomized. In comparison, in the untreated samples, approximately 70% of the reads correspond to the perfect ‘canonical’ CCAATC-5′ sequence. These data indicate END-seq as a method to sensitively detect terminal telomeric repeats while excluding the potential artifacts.</p><p>Further, we investigated whether we could detect in vivo alterations of the terminal repeat, such as those reported upon depletion of the shelterin component, POT1 (<xref ref-type="bibr" rid="bib26">Hockemeyer et al., 2005</xref>). To deplete POT1, we generated a population of HeLa cells harboring a doxycycline-inducible POT1 short hairpin RNA (shPOT1-1) construct. Doxycycline treatment resulted in reduced POT1 expression, confirming efficient knockdown (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). In agreement with previously published data, END-seq analysis showed that POT1-depleted cells have a significant reduction in terminal repeats ending with the canonical ATC-5′ sequence (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Comparison with control reads generated <italic>in silico</italic> reveals that approximately 45% of reads from POT1-depleted cells are derived from random permutations of the telomeric repeat (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>).</p><p>Lastly, we tested how depletion of either or both POT1 paralogs affected the 5′ termini of mouse telomeres. To this end, we engineered mouse embryonic stem cells (mESCs) expressing a FKBP-tagged POT1a protein (POT1a<sup>dTAG/dTAG</sup>) that is degraded when cells are treated with dTAG13 compound (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>). Using this cell line, we then generated cell lines lacking POT1b through CRISPR knockout (POT1a<sup>dTAG/dTAG</sup> POT1b<sup>-/-</sup>) (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D–F</xref>). This strategy allowed us to examine the 5′ termini of POT1-proficient ESCs, as well as systematically analyze the effect of either single or double POT1 depletion in a genetically defined background. END-seq analysis revealed that while depletion of POT1a altered 5′ termini, depletion of POT1b had no effect (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Using the KL divergence score, we determined that in the POT1-proficient and POT1b-depleted samples, approximately 70% and 85% of reads, respectively, corresponded to the perfect canonical ends. In contrast, in POT1a-depleted samples, this proportion was around 25%, regardless of POT1b status. This striking result highlights a fundamental difference between POT1a and POT1b, demonstrating that POT1a plays a dominant role in maintaining proper 5′ end processing, consistent with recently published work (<xref ref-type="bibr" rid="bib56">Tesmer et al., 2023</xref>). The stark contrast between their effects underscores the distinct functions of these paralogs and reveals an exciting new layer of telomere regulation. Collectively, these data demonstrate the effectiveness of END-seq to study terminal repeats of chromosomes.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>POT1a is the key regulator of 5′ telomere end processing in mice, distinct from POT1b.</title><p>(<bold>A</bold>) Comparison of the effect of single and double depletion of POT1a and POT1b on the percentage of telomeric reads with the indicated 5′ end sequences. The following sequences (<named-content content-type="sequence">CCCAAT</named-content>-5′, <named-content content-type="sequence">TCCCAA</named-content>-5′, and <named-content content-type="sequence">ATCCCA</named-content>-5′) are grouped and labeled as ‘Rest’. Kullback–Leibler divergence (KL divergence) analysis was used to compare the distributions across conditions. KL divergence between 0.25 and 0.375 is represented by two dots. (<bold>B</bold>) Sequence logo illustrating the conservation (in bits) of the last 6 nucleotides at the 5′ end of chromosomes in POT1-proficient, POT1a-depleted, POT1b-depleted, and POT1a/POT1b double-depleted mouse embryonic stem cells (mESCs).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original agarose gels and western blots corresponding to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B, C, and E</xref>, with relevant bands and treatments indicated.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106657-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2—source data 2.</label><caption><title>Original files for agarose gels and western blot corresponding to <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B, C, and E</xref>.</title><p>Samples used in the panels are panel B (agarose gel): samples include wild-type (WT), clone 2 (C2), and clone 3 (C3). ‘L’ indicates a 1 kb ladder. Panel C (western blot): clone 3 (C3) with and without dTAG treatment. ‘L’ indicates Precision Plus Protein Standards. FLAG and tubulin antibodies were used for the top and bottom panels, respectively. Panel E (agarose gel): samples include clone 3 (C3), clone 4 (C4), and wild-type (WT). ‘L’ indicates a 100 bp ladder.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106657-fig2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>CRISPR/Cas9-mediated endogenous knock-in and knockout of POT1a and POT1b in mouse embryonic stem cells (mESCs) with functional validation.</title><p>(<bold>A</bold>) Schematic of the POT1a genomic locus (red) and repair template containing homology arms to the Pot1a locus (red), selection marker blasticidin (BSD), 3xflag tag, and FKBP12<sup>F36V</sup> (blue). Scissors represent the CRISPR/Cas9 cut site used for endogenous knock-in generation. Sanger sequencing confirms the newly generated FKBP12<sup>F36V</sup> and <italic>POT1a</italic> junction. (<bold>B</bold>) PCR genotyping to detect knock-in was performed. (<bold>C</bold>) Western blot analysis of mESCs expressing Flagx3-FKBP12<sup>F36V</sup>::POT1a treated with or without dTAG13 (500 nM) for 24 hr. (<bold>D</bold>) Schematic of the POT1b genomic locus showing exons targeted by sgRNAs (exon 2, E2, in red and exon 4, E4, in blue) and untargeted exons (gray), with wild-type and knockout conditions indicated. Scissors mark the CRISPR/Cas9 cut site used to generate the knockout cell line. Primers for genotyping are labeled as P1, P2, and P3 with arrows. Sanger sequencing confirms the knock-out by generation of newly generated exon 2 and exon 4 junction, resulting in a deletion and frameshift. (<bold>E</bold>) PCR genotyping to detect knockdown was performed. (<bold>F</bold>) Relative expression level of POT1b in mESCs compared to control. (<bold>G</bold>) Comparison of experimental data presented in <xref ref-type="fig" rid="fig2">Figure 2A</xref> with modeled predictions to assess the impact of varying degrees of randomization on the <named-content content-type="sequence">CCAATC</named-content>-5′ termini.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original agarose gels and western blots corresponding to <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B, C and E</xref>, with relevant bands and treatments indicated.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106657-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Original files for agarose gels and western blot corresponding to <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B, C and E</xref>.</title><p>Samples used in the panels are panel B (agarose gel): samples include wild-type (WT), clone 2 (C2), and clone 3 (C3). ‘L’ indicates a 1 kb ladder. Panel C (western blot): clone 3 (C3) with and without dTAG treatment. ‘L’ indicates Precision Plus Protein Standards. FLAG and tubulin antibodies were used for the top and bottom panels, respectively. Panel E (agarose gel): samples include clone 3 (C3), clone 4 (C4), and wild-type (WT). ‘L’ indicates a 100 bp ladder.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-106657-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>The terminal 5′ sequence in ALT-positive cells is canonical</title><p>Having established that END-seq efficiently captures the terminal repeat of chromosome ends, we sought to investigate whether ALT-positive cells have the same tight regulation of terminal repeats as telomerase-positive cells. We performed END-seq on three ALT-positive cell line: G292, SAOS2, and U2OS. Our analysis shows that in ALT cells, the vast majority of telomeric reads (82–98% across 3 cell lines and 11 biological repeats) correspond to the C-rich strand (<xref ref-type="fig" rid="fig3">Figure 3A–C</xref>), consistent with non-ALT cells and the expected pattern for a one-ended-DSB. Motif analysis revealed that the majority of telomeric reads in all three tested cell lines start with the canonical ATC-5′ sequence (<xref ref-type="fig" rid="fig3">Figure 3D</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–C</xref>). These data suggest that regulation of the terminal 5′ of ends of chromosomes occurs independently of the mechanism of telomere elongation. To test this hypothesis, we depleted POT1 in U2OS cells using two different doxycycline-inducible shRNAs (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>). POT1 depletion resulted in formation of 53BP1 foci (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>), consistent with POT1’s established role in suppressing the DNA damage response at chromosome ends (<xref ref-type="bibr" rid="bib26">Hockemeyer et al., 2005</xref>; <xref ref-type="bibr" rid="bib15">Denchi and de Lange, 2007</xref>). Next, we performed END-seq to evaluate the effect of POT1 depletion on the terminal sequence. The data show that, similarly to telomerase-positive HeLa cells, depletion of POT1 dramatically altered the 5′ natural termini in ALT-positive cell lines (<xref ref-type="fig" rid="fig3">Figure 3G</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Alternative lengthening of telomeres (ALT) cells have precise 5′ termini.</title><p>(<bold>A</bold>–<bold>C</bold>) Number of telomeric reads containing at least four consecutive telomeric repeats corresponding to the G-rich (green) and C-rich (red) strands in the ALT-positive G292, SAOS2, and U2OS cell lines. Telomeric reads are normalized to the total number of reads identified by END-seq and are represented as reads per million (RPM). (<bold>D</bold>) Sequence logo representing the conservation at chromosome ends. A sequence logo representing the conservation (bits) of the last 6 nucleotides at the 5′ end of chromosomes in ALT cells. Fraction of reads with <named-content content-type="sequence">CCAATC</named-content> as 5′ end is displayed. (<bold>E</bold>) Cells expressing either a nontargeting shRNA (shScr) or a shRNA targeting POT1 (shPOT1-1) were stained for 53BP1 (red) and telomeric DNA (<named-content content-type="sequence">TTAGGG</named-content>, green). The scale bar represents 10 μm. (<bold>F</bold>) Quantification of the data shown in (<bold>E</bold>). Graphs indicated the percentage of cells that have at least five telomere dysfunctional foci (TIF) with 53BP1 co-localizing at telomeres. (<bold>G</bold>) Percentage of telomeric reads that have the indicated sequence as a 5′ sequence that have as a 5′ end. The following sequences (<named-content content-type="sequence">CCCAAT</named-content>-5′, <named-content content-type="sequence">TCCCAA</named-content>-5′, and <named-content content-type="sequence">ATCCCA</named-content>-5′) are grouped and labeled as ‘Rest’. Cells expressing either a nontargeting shRNA (shScr) or a shRNA targeting POT1 (shPOT1-1 and shPOT1-2) were harvested 3 days post induction and analyzed by END-seq. Kullback–Leibler divergence (KL divergence) analysis was used to compare the distributions of the individual conditions. KL divergence between 0.25 and 0.375 is represented by two dots (●●), KL divergence greater than 0.375 is represented by three dots (●●●).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of 5′ termini and of presence of variant telomeric repeats in U2OS.</title><p>(<bold>A</bold>–<bold>C</bold>) Distribution of telomeric reads across biological replicates of ALT-positive G292 (<bold>A</bold>), SAOS2 (<bold>B</bold>), and U2OS Cells. The following sequences (<named-content content-type="sequence">CCCAAT</named-content>-5′, <named-content content-type="sequence">TCCCAA-</named-content>5′, and<named-content content-type="sequence"> ATCCCA</named-content>-5′) are grouped and labeled as ‘Rest’. (<bold>D</bold>) Relative expression level of POT1 in U2OS cells expression of two different inducible shRNA against POT1 (shPOT1-1 and shPOT1-2) compared to control (shScr) after 3 days of shRNA induction by doxycycline. (<bold>E</bold>) Percentage of canonical telomeric reads (CTRs) and variant telomeric reads (VTRs) within the first 30 nucleotides from the 5′ of the terminal of Illumina reads from U2OS or HeLa cells.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig3-figsupp1-v1.tif"/></fig></fig-group><p>Next, we asked whether ALT cells are more likely to contain variant telomeric repeats (VTRs) in the terminal portions of chromosome ends. VTRs have been shown to occur frequently in telomeric reads isolated from ALT-positive cells (<xref ref-type="bibr" rid="bib14">Conomos et al., 2012</xref>). To establish whether VTRs in ALT cells are contained within terminal repeats, we assessed the frequency of non-canonical telomeric repeats within the first 30 nucleotides from the 5′ of the Illumina reads from U2OS (1.93%) and HeLa (1.93%) cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). This result shows that in ALT-positive cells, VTRs do not occur more frequently than non-ALT cells within the very terminal portion of chromosome ends. Due to the short read lengths used in this approach, we cannot determine whether VTRs in ALT cells are specifically excluded from the terminal region of chromosome ends.</p></sec><sec id="s2-3"><title>Frequent occurrence of ssDNA in ALT telomeres</title><p>Having demonstrated that the 5′ terminal repeats in ALT cells are indistinguishable from non-ALT cells, we next asked whether the presence of single-stranded DNA (ssDNA) could be a unique feature of telomeric DNA in ALT-positive cells. Previous work provided indirect evidence for the presence of single-stranded telomeric DNA in ALT-positive cells, such as staining for RPA at telomeres, and FISH under native conditions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–D</xref>; <xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Grudic et al., 2007</xref>). To test whether telomeres in ALT cells contain ssDNA, we employed S1-END-seq as a direct measure for the presence of ssDNA (<xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref>). For this method, the S1 nuclease is used to convert any ssDNA into DSBs which are detected by END-seq. We anticipated that if telomeres do not contain any single-stranded telomeric DNA in addition to the 3′ overhang, telomeric S1-END-seq reads will be indistinguishable from the signal obtained using standard END-seq, corresponding to one-ended DNA ends (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). However, S1-mediated cleavage of ssDNA within the internal telomeric tract will generate two-ended DSBs within telomeres. A DSB within telomeres would result in telomeric reads corresponding both to the C-rich and the G-rich strands (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To test this prediction, we performed S1-END-seq on a panel of ALT-positive and ALT-negative (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). S1-END-seq in ALT-negative cells revealed only C-strand telomeric reads excluding the presence of a significant amount of ssDNA within the telomeric tract in these cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). By contrast, performing S1-END-seq on a panel of ALT-positive cell lines revealed that G-rich and C-rich telomeric reads were detected at similar frequencies (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). These data show that telomeres in ALT-positive cells contain frequent regions of single-stranded DNA. Furthermore, our data shows that the ratio of C-rich to G-rich reads in S1-END-seq data can distinguish ALT-negative (0.98–0.99) from ALT-positive cell lines (0.4–0.58). Based on this ratio, we estimate that the ALT-positive cells analyzed here contain a minimum of three single-stranded telomeric DNA regions per chromosome end (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F and G</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Alternative lengthening of telomeres (ALT) telomeres are readily distinguished due to presence of telomeric ssDNA by sequencing.</title><p>(<bold>A</bold>) Schematic representation of the S1-END-seq method applied to telomeres containing either an internal ssDNA region (left) or only the natural G-rich overhang (right). S1 nuclease treatment cleaves ssDNA regions generating two-ended double-strand break (DSB) (left) or one-ended DSB (right). DNA ends are ligated to biotinylated adaptors, purified, and subsequently sequenced by NGS. Reads originating from the double-ended DSB align to either side of the break (left), resulting in C-rich (red) and G-rich (green) reads. Reads originating from the single-ended chromosome ends align only to the C-rich template (red). (<bold>B</bold>) Proportion of telomeric reads (containing at least four consecutive telomeric reads) corresponding to G-rich reads (green) or C-rich reads (red). (<bold>C</bold>, <bold>D</bold>) Proportion of telomeric reads (containing at least four consecutive telomeric reads) corresponding to G-rich reads (green) or C-rich reads (red) in BLM-proficient (U2OS) or -deficient (BML<sup>-/-</sup>) cells by END-seq (<bold>C</bold>) or S1-seq (<bold>D</bold>). (<bold>E</bold>) Native telomeric FISH (ssTelo) in BLM-proficient (U2OS) or -deficient (BML<sup>-/-</sup>) cells either left untreated (control) or expressing TRF1-Fok1. The scale bar represents 10 μm. (<bold>F</bold>) Quantification of the data shown in (E), cells with five ssTelo signal (or greater) were scored as positive. When indicated, cells were induced to express the TRF1-Fok1 nuclease for 24 hr prior to harvesting. (<bold>G</bold>, <bold>H</bold>) Proportion of telomeric reads (containing at least four consecutive telomeric reads) corresponding to G-rich reads (green) or C-rich reads (red) in BLM-proficient (U2OS) or -deficient (BML<sup>-/-</sup>) cells expressing TRF1-Fok1 by END-seq (<bold>G</bold>) or S1-seq (<bold>H</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>ssDNA in alternative lengthening of telomeres (ALT) telomeres.</title><p>(<bold>A</bold>, <bold>B</bold>) Representative images and quantification of the percentage of ALT-positive U2OS cells and ALT-negative HeLa cells with more than 5 RPA foci colocalizing to TRF2. Data shown repeated in triplicate with a minimum of 250 cells counted per cell line. Error bars represent the standard error of the mean where n=3. The scale bar represents 10 μm. (<bold>C</bold>, <bold>D</bold>) Representative images and quantification of the percentage of ALT-positive U2OS cells and ALT-negative HeLa cells with more than five FISH foci where the staining is done under native conditions (ssTelo) to label single-stranded G-rich telomeric DNA (ssTeloG, green) or C-rich telomeric DNA (ssTeloC, red). Data shown repeated in triplicate with a minimum of 250 cells counted per cell line. Error bars represent the standard error of the mean where n=3. The scale bar represents 10 μm. (<bold>E</bold>) Number of reads containing at least four consecutive telomeric repeats corresponding to the G-rich (green) and C-rich (red) strands in a panel of ALT-negative and ALT-positive cells. Telomeric reads are normalized to the total number of reads identified by S1-END-seq and are represented as reads per million (RPM). (<bold>F</bold>) Schematics representing the expected number of C-strand and G-strand reads obtained by S1-END-seq in the absence of ssDNA regions within telomeres (1 end), or in the presence of 1 or 2 ssDNA. Bottom graph represents the expected ratio of C/G reads normalized to the total number of telomeric reads. (<bold>G</bold>) Table representing the expected number of C-strand and G-strand reads following a S1-END-seq in the presence of the listed number of ssDNA region with a single chromosome end. (<bold>H</bold>) Percentage of canonical telomeric reads (CTRs) and variant telomeric reads (VTRs) within the first 30 nucleotides from the 5′ of the terminal of Illumina reads from END-seq and S1-END-seq libraries of U2OS Cells. (<bold>I</bold>) Percentage of telomeric reads that have the indicated sequence as a 5′ sequence that have as a 5′ end. The following sequences (<named-content content-type="sequence">CCCAAT</named-content>-5′, <named-content content-type="sequence">TCCCAA</named-content>-5′, and <named-content content-type="sequence">ATCCCA</named-content>-5′) are grouped and labeled as ‘Rest’. Cells expressing either a nontargeting shRNA (shScr) or a shRNA targeting POT1 (shPOT1-1 and shPOT1-2) were harvested 3 days post induction and analyzed by S1-END-seq. Kullback–Leibler divergence (KL divergence) analysis was used to compare the distributions of the individual conditions. KL divergence less than 0.125 are considered nonsignificant and indicated as n/s.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-106657-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We also investigated whether reads detected by S1-END-seq are more likely to contain VTRs compared to the terminal portions of telomeres. We compared the frequency of VTRs within the first 30 nucleotides of the S1-END-seq reads from U2OS libraries (3.8%) to their control END-seq U2OS libraries (1.93%). This shows that the frequency of VTRs is higher in the internal portions of chromosome ends compared to the terminal portions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H</xref>).</p><p>To determine whether the presence of ssDNA at telomeres in ALT cells is a feature intrinsic to these cells or a feature of the ALT-mediated telomere elongation, we measured the levels of ssDNA at telomeres in cells lacking BLM. Depletion of BLM is sufficient to suppress ALT-mediated telomere elongation, as shown by the loss of ALT-associated features and progressive telomere shortening (<xref ref-type="bibr" rid="bib28">Jiang et al., 2024</xref>; <xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">O’Sullivan et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Min et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Sobinoff et al., 2017</xref>). As expected, we found similar levels of C-rich and G-rich reads in S1-END-seq data from U2OS cells (C/G strand ratio: 0.55, <xref ref-type="fig" rid="fig4">Figure 4D</xref>), indicating a minimum of 5 ssDNA regions per chromosome end. By contrast, BLM-deficient U2OS cells show a bias toward C-rich reads (C/G strand ratio: 0.7, <xref ref-type="fig" rid="fig4">Figure 4D</xref>), indicating that these cells have reduced levels of ssDNA at chromosome ends compared to the parental ALT-positive U2OS cell line (at least one ssDNA region per chromosome end). Given that BLM helicase contributes to telomere stability by resolving secondary structures and ensures proper telomeres replication regardless of telomere maintenance mechanism (<xref ref-type="bibr" rid="bib4">Barefield and Karlseder, 2012</xref>; <xref ref-type="bibr" rid="bib17">Drosopoulos et al., 2015</xref>; <xref ref-type="bibr" rid="bib49">Sfeir et al., 2009</xref>), it is possible that ssDNA detected in the absence of BLM is due to replication fidelity. Contrary to this, most of the reads detected in both BLM-proficient and deficient cells by END-seq were coming from the C-strand (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). As a control, we tested whether artificially introducing DSBs at telomeres using the TRF1-FokI construct (<xref ref-type="bibr" rid="bib11">Cho et al., 2014</xref>) would abrogate the difference in BLM-proficient and -deficient cells. Expression of TRF1-Fok1 results in DSBs at telomeres, which are detected as the appearance of G-rich reads by END-seq in both BLM-proficient and BLM-deficient cells (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Expression of the TRF1-FokI nuclease in BLM-deficient cells was sufficient to induce single-stranded telomeric DNA at telomeres as seen by ssTelo signal (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>) as well as a C/G strand ratio close to what was seen in U2OS cells (<xref ref-type="fig" rid="fig4">Figure 4H</xref>).</p><p>Collectively, these data show that cells undergoing ALT have multiple single-stranded DNA regions that vastly exceed the number of chromosome ends. Accumulation of single-stranded telomeric DNA is tightly linked to the ALT process itself.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>END-seq as an unbiased tool to study the terminal telomeric repeat</title><p>Here, we show that END-seq can efficiently capture 5′ chromosome termini, providing a high-resolution and unbiased approach to studying the terminal portion of chromosome ends. We found that by END-seq, chromosome ends are detected as one-ended DSBs corresponding to the 5′ C-rich telomeric strand. Our data show that, in agreement with previous work (<xref ref-type="bibr" rid="bib48">Sfeir et al., 2005</xref>), most chromosomes have the sequence ATC as the 5′ end. END-seq has several advantages over alternative approaches: it is unbiased since it does not rely on capture oligos, it can be applied to telomeres of any length, and does not require any prior knowledge of the subtelomeric sequence. While END-seq is designed to capture chromosome ends in an unbiased manner, we cannot exclude the possibility that certain telomeric structures may hinder detection, potentially leading to underrepresentation of a subset of telomeres. Nevertheless, we have been able to define the terminal identity of chromosome ends in cells with long telomeres, such as murine cells and ALT-positive cells, as well as cells with poorly characterized subtelomeric regions, such as canine cells. These data show that the ATC-5′ sequence appears to be universal, highlighting a conserved mechanism of end-processing in mammalian cells. We also examined the effect of the depletion of POT1 paralogs on the 5′ chromosome termini in mouse cells. While POT1a depletion altered the sequence at 5′ ends, POT1b depletion had no effect. This finding adds to the growing evidence that POT1a and POT1b have distinct functions at mouse telomeres (<xref ref-type="bibr" rid="bib56">Tesmer et al., 2023</xref>; <xref ref-type="bibr" rid="bib15">Denchi and de Lange, 2007</xref>; <xref ref-type="bibr" rid="bib57">Wu et al., 2006</xref>; <xref ref-type="bibr" rid="bib39">Nurk et al., 2022</xref>; <xref ref-type="bibr" rid="bib27">Hockemeyer et al., 2006</xref>; <xref ref-type="bibr" rid="bib24">Gu et al., 2021</xref>).</p></sec><sec id="s3-2"><title>Canonical POT1-dependent regulation of the terminal sequences in ALT-positive cells</title><p>Our data show that ALT-positive cells, which use recombination-based mechanisms for telomere elongation, have the same regulation of terminal repeats as telomerase-positive cells. END-seq analysis of three different ALT-positive cell lines (G292, SAOS2, and U2OS) revealed that the majority of telomeric reads correspond to C-rich reads starting with the canonical <named-content content-type="sequence">CCAATC</named-content>-5′ sequence. This indicates that the regulation of the terminal 5′ end of chromosome ends occurs independently of the telomere elongation mechanism and that ALT-based recombination does not alter this process. Furthermore, our data show that POT1 is critical, even in U2OS cells, to define the 5′ end termini of telomeres.</p></sec><sec id="s3-3"><title>Single-stranded DNA in ALT telomeres</title><p>Using the unbiased S1-END-seq approach, we show that the presence of single-stranded telomeric DNA characterizes ALT-positive cells. This property of ALT is unique in that cells can be readily classified as ALT-positive or ALT-negative based on the occurrence of S1-cuts within the telomeric reads (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The observed single-stranded telomeric DNA may arise from various sources, including R-loops, D-loops, internal DNA loops (i-loops), and extrachromosomal circles, which are known to be prevalent in ALT (<xref ref-type="bibr" rid="bib16">Dilley et al., 2016</xref>; <xref ref-type="bibr" rid="bib25">Henson et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Mazzucco et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Arora et al., 2014</xref>).</p><p>Notably, our findings align with previous indirect evidence suggesting that ALT-positive cells exhibit increased levels of telomeric ssDNA, RPA-staining, and FISH under native conditions (<xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Grudic et al., 2007</xref>; <xref ref-type="bibr" rid="bib13">Claude et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Frank et al., 2022</xref>). Based on our data, we can now conclude that these assays are all indeed detecting the telomeric ssDNA. Due to the nature of S1 cleavage and the repetitive nature of telomeric reads, it is impossible to establish how many regions within telomeres have ssDNA or the average length of the single-stranded DNA tract within telomeres. However, based on the relative ratio between G-rich and C-rich strands, we estimate that there are at least five distinct regions of single-stranded DNA for each chromosome end in ALT-positive cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). The origin of the observed single-stranded telomeric DNA remains to be determined. It is possible that, in ALT cells, partially single-stranded extrachromosomal DNA in the form of C-circles is captured by the S1-END-seq approach. Alternatively, we may be detecting intermediates of the ALT process at chromosome ends or single-stranded DNA generated by strand displacement due to the presence of R-loops and/or G-quadruplexes. Future studies will be needed to elucidate the mechanisms underlying the generation of ssDNA at telomeres in ALT cells. Nevertheless, our findings provide a rationale for using ssTelo as a biomarker for ALT-positive cell detection, offering new avenues for studying and targeting ALT-driven cancers (<xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Claude et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Frank et al., 2022</xref>; <xref ref-type="bibr" rid="bib47">Quintanilla et al., 2025</xref>).</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">U2OS</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-96, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0042">CVCL_0042</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HeLa 1.2.11</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib54">Takai et al., 2010</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_7908">CVCL_7908</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">GM847</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Henson et al., 2009</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_7908">CVCL_7908</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">SUSM1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib25">Henson et al., 2009</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_4903">CVCL_4903</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">SAOS-2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-85, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0548">CVCL_0548</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">G292</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1423, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_2909">CVCL_2909</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">U2OS BLM<sup>-/-</sup></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-3216, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:CVCL_0063">CVCL_0063</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">MEFs</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Okamoto et al., 2013</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">mESC, E14</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Materials and methods’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">mESC, E14 <italic>Pot1a::3×FLAG–FKBP12<sup>F36V</sup></italic></td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Materials and methods’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">mESC E14 <italic>Pot1b<sup>-/-</sup></italic></td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Materials and methods’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">mESC E14 <italic>Pot1a::3×FLAG–FKBP12<sup>F36V</sup> Pot1b<sup>-/-</sup></italic></td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Materials and methods’</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>Canis lupus familiaris</italic>)</td><td align="left" valign="bottom">KOS</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom"/><td align="left" valign="bottom">See ‘Materials and methods’</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-TRF2 (rabbit polyclonal)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">Cat# NB110-57130, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_844199">AB_844199</ext-link></td><td align="left" valign="bottom">IF (1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RPA32/RPA2 (4E4) (rat monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 2208, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_2238543">AB_2238543</ext-link></td><td align="left" valign="bottom">IF (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Myc-Tag(9B11) (mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 2276, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_331783">AB_331783</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-53BP1 (rabbit polyclonal)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">Cat# NB100-304, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_10003037">AB_10003037</ext-link></td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pRSIT16-U6Tet-sh-EF1-TetRep-2A-Puro</td><td align="left" valign="bottom">Cellecta</td><td align="left" valign="bottom">Cat# SVSHU6TEP-L</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pLenti- CMV TRE3G Puro FLAG-DD-ER-mCherry-TRF1-FokI WT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib16">Dilley et al., 2016</xref></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">Plasmid</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">shPOT1 (<named-content content-type="sequence">TGTAGCTTGATCAGACACTTA</named-content>)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">shRNA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">shPOT1-2 (<named-content content-type="sequence">TATGTATGCTAAATTGGATGG</named-content>)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">shRNA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">hPOT1_F (qPCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">CAGAACCTGACGACAGCTTTCC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">hPOT1_R (qPCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">GCACATAGTGGTGTCCTCTCCA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">hGAPDH_F (qPCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′- <named-content content-type="sequence">GTCTCCTCTGACTTCAACAGCG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">hGAPDH</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">ACCACCCTGTTGCTGTAGCCAA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mPOT1b_F (qPCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">TTCGGCCCCAGTAGCACCTT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mPOT1b</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">TCTCTTGCTTAAAGTACGCAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mGAPDH_F (qPCR primer)</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">TGTGTCCGTCGTGGATCTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mGAPDH</td><td align="left" valign="bottom">IDT</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">5′-<named-content content-type="sequence">TTGCTGTTGAAGTCGCAGGAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">END-seq adaptor 1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">5′ -phosphate -<named-content content-type="sequence">GATCGGA AGAGCGTCG TGTAGGGAAAGAGTGUU</named-content>[Biotin-dT]U[BiotindT]<named-content content-type="sequence">UUACACTC TTTCCCTACACGACGCTCTTCCGATC</named-content>*T-3′</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">END-seq adaptor 2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">5′ -phosphate -<named-content content-type="sequence">GATCGGA AGAGCACAC GTCUUUUUUUUAGACGTGTGCTCTTCCGA TC</named-content>*T-3</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TelC-Cy3</td><td align="left" valign="bottom">PNABio</td><td align="left" valign="bottom">Cat# F1002</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">TelG-Cy3</td><td align="left" valign="bottom">PNABio</td><td align="left" valign="bottom">Cat# F1006</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">KAPA HiFi HotStart ReadyMix</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# KK2602</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">KAPA Library Quantification Kit</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# KK4824</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Plus Mini Kit</td><td align="left" valign="bottom">QIAGEN</td><td align="left" valign="bottom">Cat# 74104</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">SuperScript II Reverse Transcriptase</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 18064014</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Power SYBR Green PCR Master</td><td align="left" valign="bottom">Fisher Scientific</td><td align="left" valign="bottom">Cat# 4368577</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Qubit dsDNA HS assay kit</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# Q32851</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Exonuclease T (ExoT)</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0265L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Klenow Fragment (3’→ 5′ exo-)</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0212L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Quick Ligation Kit</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M2200L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">USER enzyme</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M5505L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">T4 DNA Polymerase</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0203L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">T4 Polynucleotide Kinase</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0201L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DNA Polymerase I, Large (Klenow) Fragment</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# M0210L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S1 Nuclease</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# EN0321</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S1-END-seq KM12</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GEO # GSE203632</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S1-END-seq RKO</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GEO # GSE203632</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S1-END-seq SW48</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GEO # GSE203632</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">S1-END-seq SW620</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">GEO # GSE203632</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Methods</title><sec id="s4-1-1"><title>Cell culture</title><p>Human, mouse, and dog cell lines were grown in DMEM medium supplemented with 10% fetal bovine serum (FBS) and 0.5 mg/ml penicillin, streptomycin, and L-glutamine (Gibco) and cultured at 37°C and 5% CO<sub>2</sub>. HeLa cells used in this study were HeLa1.2.11. G292 cells were grown in McCoy medium supplement with 15% FBS and 0.5 mg/ml penicillin, streptomycin, and L-glutamine (Gibco). Cell lines were tested for mycoplasma contamination. BLM knock-out cells were previously described in <xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>, mESC E14 and canine cell line KOS were kind gifts of the Scripps Research Institute Genomics Core Facility and Dr. Amy LeBlanc (NCI), respectively.</p></sec><sec id="s4-1-2"><title>Generation of mESC lines</title><p>Knockout and knock-in cell lines were generated via CRISPR/Cas9 gene targeting by transient transfection using Lipofectamine 2000 (Thermo Fisher Scientific). Cells were transfected with a plasmid encoding SpCas9 (px330) and a plasmid encoding specific gRNAs (backbone Addgene 41824). To introduce the dTAG13 controllable FKBP-tag POT1a in mESCs via homologous recombination-mediated repair, a synthetic repair template containing homology arms to the <italic>Pot1a</italic> locus, a blasticidin resistance marker, a 3xFLAG tag, and an FKBP tag was used, along with 2 sgRNA targeting the 5′ region of <italic>Pot1a</italic> (guide 1: 5′- <named-content content-type="sequence">TTACATTAGTGCTAATCCAA</named-content>-3′, and guide 2: 5′-<named-content content-type="sequence">TTTTCATCAAACAATGTCTT</named-content>-3′). To generate POT1b<sup>-/-</sup> cells, two gRNAs were used: guide 1 (5′-<named-content content-type="sequence">GTTCCTTTGCTTAAGTACGG</named-content>-3′) and guide 2 (5′-<named-content content-type="sequence">GACATTTGATGGCACCTTAG</named-content>-3′). Transfected cells were single-cell cloned, and resulting clones were screened by PCR to confirm the desired genomic deletion, which was further validated by Sanger sequencing.</p></sec><sec id="s4-1-3"><title>Lentiviral-mediated gene manipulation</title><p>Lentiviral particles were generated by transfection into HEK293T followed by isolation and transduction as previously described (<xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>). Lentiviral expression was achieved with the following constructs and procedure:</p><sec id="s4-1-3-1"><title>POT1 depletion</title><p>sgRNA targeting POT1 (POT1-1: <named-content content-type="sequence">TGTAGCTTGATCAGACACTTA</named-content>, POT1-2: <named-content content-type="sequence">TATGTATGCTAAATTGGATGG</named-content>) were cloned into an inducible lentiviral vector (pRSITEP-U6Tet-sh-EF1-TetRep-2A-Puro) (Cellecta). Following infection, cells were treated with 1 μg/ml of doxycycline to induce shRNA expression and harvested 3 days later.</p></sec><sec id="s4-1-3-2"><title>TRF1-Fok1 expression</title><p>pLenti-CMV-TRE3G-ER-TRF1-Fok1 expressing plasmids (<xref ref-type="bibr" rid="bib16">Dilley et al., 2016</xref>) were a kind gift from Agnel Sfeir. Infected cells were treated with 1 μg/ml of doxycycline and 0.6 μM of 4-hydroxytamoxifen (4-OHT) to induce TRF1-Fok1 and harvested 24 hr later.</p></sec></sec></sec><sec id="s4-2"><title>RNA isolation and qRT-PCR</title><p>Total RNA was extracted from cells using the RNeasy Plus Mini Kit (QIAGEN), and cDNA was made using SuperScript II Reverse Transcriptase (Thermo Fisher). qPCR was performed using Power SYBR Green PCR Master (Fisher Scientific). Samples were run on a Bio-Rad CFX Opus 96 and analyzed on Bio-Rad CFX Maestro. The following primers were used in this study:</p><list list-type="simple" id="list1"><list-item><p>hPOT1: 5′-<named-content content-type="sequence">CAGAACCTGACGACAGCTTTCC</named-content> and 5′-<named-content content-type="sequence">GCACATAGTGGTGTCCTCTCCA</named-content>.</p></list-item><list-item><p>hGAPDH: 5′-<named-content content-type="sequence">GTCTCCTCTGACTTCAACAGCG</named-content> and <named-content content-type="sequence">ACCACCCTGTTGCTGTAGCCAA</named-content>.</p></list-item><list-item><p>mPOT1b: 5′-<named-content content-type="sequence">TTCGGCCCCAGTAGCACCTT</named-content> and 5′-<named-content content-type="sequence">TCTCTTGCTTAAAGTACGCAG</named-content>.</p></list-item><list-item><p>mGAPDH: 5′-<named-content content-type="sequence">TGTGTCCGTCGTGGATCTGA</named-content> and 5′-<named-content content-type="sequence">TTGCTGTTGAAGTCGCAGGAG</named-content>.</p></list-item></list></sec><sec id="s4-3"><title>Immunofluorescence (IF) and FISH-based imaging</title><p>IF, IF-FISH, and ssTelo staining were carried out as described previously (<xref ref-type="bibr" rid="bib32">Loe et al., 2020</xref>; <xref ref-type="bibr" rid="bib2">Azeroglu et al., 2024</xref>).</p><p>PNA probes used in this study were TelC-Cy3 (PNABio, Cat# F1002) and TelG-Cy3 PNA probe (PNABio, Cat# F1006).</p><p>Primary antibodies used in this study were TRF2 (NB110-57130, Novus Biologicals, rabbit), RPA32/RPA2 (2208, Cell Signaling, rat), Myc (2276, Cell Signaling, mouse), and 53BP1 (NB100-304, Novus Biologicals, rabbit).</p></sec><sec id="s4-4"><title>Imaging and image analysis</title><p>Images were acquired using a Zeiss Axio Imager M2 with an Axiocam 702 camera and ZEN 2.6 (blue edition) software; for each experiment and condition, a minimum of 250 cells were imaged. Final figures were assembled using Adobe Photoshop 25.7.0 and Adobe Illustrator 28.5.</p></sec><sec id="s4-5"><title>END-seq and S1-END-seq</title><p>For END-seq and S1-END-seq, 6–20 × 10<sup>6</sup> cells were collected, embedded in 1% agarose plugs, and processed as previously reported (<xref ref-type="bibr" rid="bib9">Canela et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Matos-Rodrigues et al., 2022</xref>). For mouse spleen library, mice were euthanized with CO<sub>2</sub> following ethical guidelines, and the spleens were surgically removed. Spleen tissues were mashed through a 70 μm cell strainer to obtain a single-cell suspension. The suspension was then centrifuged for 5 min at 300 × <italic>g</italic>, the pellet was washed with ice-cold PBS three times before proceeding with library preparation. Briefly, plugs were incubated with proteinase K solution for 1 hr at 50°C and then for 7 hr at 37°C, followed by consecutive washes in a wash buffer (10 mM Tris, pH 8.0, and 50 mM EDTA) and TE (10 mM Tris, pH 8.0, and 1 mM EDTA). Washed plugs were then treated with RNAseA (Puregene, QIAGEN), washed again in Wash Buffer, and stored at 4°C for up to 2 weeks. End blunting, A-tailing, and ligation to biotinylated hairpin adaptor 1 (ENDseq-adaptor-1, 5′-Phos-<named-content content-type="sequence">GATCGGAAGAGCGTCGTGTAGGGAAAGAGTGUU</named-content>[Biotin-dT]U[Biotin-dT]<named-content content-type="sequence">UUACACTCTTTCCCTACACGACGCTCTTCCGATC</named-content>∗T-3′ [∗phosphorothioate bond]) were performed in the plug to minimize shearing and in vitro damage. Following this, high molecular weight DNA was isolated from agarose plugs and fragmented by sonication. Subsequently, adaptor-ligated fragments were captured with streptavidin-coated beads and sonication-created ends were repaired, A-tailed, and ligated with a distal adaptor (ENDseq-adaptor-2, 5′-Phos-<named-content content-type="sequence">GATCGGAAGAGCACACGTCUUUUUUUUAGACGTGTGCTCTTCCGATC</named-content>∗T-3′ [∗phosphorothioate bond]). Subsequent PCR amplification resulted in ready-to-sequence libraries where the sequenced first base corresponds precisely to the first base of the blunted DSB on either side of the break. For S1-END-seq, proteinase K and RNAseA-treated plugs were treated with 100 U of S1 nuclease (Thermo Fisher) at 37°C for 30 min and the reaction was terminated by the addition of EDTA to a final concentration of 10 mM. S1-treated plugs were then processed through the standard END-seq protocol. For T7 treatment, proteinase K and RNAseA-treated plugs were incubated with 50 U of T7 exonuclease (NEB) at 37°C for 30 min before processing through the standard END-seq protocol.</p><p>The libraries were sequenced on the Nextseq 550 or Nextseq 2000 platform (Illumina) using 75-bp single-end read kits. For each treatment condition, the control (nontreated) and sample libraries were sequenced in parallel in the same flow cell.</p></sec><sec id="s4-6"><title>Telomeric motif detector and quantifier</title><p>We developed a Python script, ‘getTelomereENDseq’, to analyze gzipped FASTQ files for the presence of telomeric motifs in DNA sequences on a command-line environment using a Linux-based operating system and the statistical environment RStudio. The script identifies sequences containing G-rich and C-rich telomeric repeats, quantifies their occurrences, and calculates their relative frequencies. It takes a gzipped FASTQ file as input, and the minimum number of telomeric repeats is required. It generates two output files: one with sequences containing G-rich motifs and another with sequences containing C-rich motifs. For this study, we used a minimum of four consecutive <named-content content-type="sequence">TTAGGG</named-content> repeats for G-rich reads and a minimum of four consecutive <named-content content-type="sequence">CCCTAA</named-content> repeats for C-rich reads. Following this, in RStudio, using the <italic>stringi</italic>, <italic>ggseqlogo</italic>, <italic>ggplot2</italic>, <italic>ggsci</italic>, and <italic>tidyverse</italic> packages, the telomeric reads were trimmed by the last six nucleotides, reversed, and organized into data frames. These data frames were then used to plot the frequencies of telomeric repeats or motifs.</p></sec><sec id="s4-7"><title>Statistical analysis and data visualization</title><p>We used RStudio and GraphPad Prism v10 for data visualization and statistical analysis. Statistical analyses are specified in figure legends. For microscopy data, p &lt; 0.05 was considered statistically significant, and p values were assessed by unpaired parametric <italic>t</italic>-test. The sample size was not predetermined. Statistical analyses are specified in the figure legends. We used KL divergence to compare the distributions of frequencies of telomeric repeats between different samples. The KL divergence is a measure of the difference between two probability distributions. It quantifies how one probability distribution diverges from a second, expected distribution. To compute KL divergence, we used the philentropy package in RStudio. For this study, KL divergence values less than 0.125 are considered nonsignificant, and the rest assigned as follows: ● indicates KL divergence value between 0.125 and 0.25, ●● indicates a value between 0.25 and 0.375, and ●●● indicates a value greater than 0.375.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Methodology</p></fn><fn fn-type="con" id="con3"><p>Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Resources, Methodology</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Investigation, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-106657-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The accession number for the datasets reported in this paper is available at GEO with accession number: GSE301770.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Azeroglu</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Pavani</surname><given-names>R</given-names></name><name><surname>Sandhu</surname><given-names>R</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name><name><surname>Lazzerini Denchi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2025">2025</year><data-title>Conserved and Unique Features of Terminal Telomeric Sequences in ALT-Positive Cancer Cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301770">GSE301770</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Matos-Rodrigues</surname><given-names>G</given-names></name><name><surname>van Wietmarschen</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Koussa</surname><given-names>N</given-names></name><name><surname>Pavani</surname><given-names>R</given-names></name><name><surname>Callen</surname><given-names>E</given-names></name><name><surname>Nathan</surname><given-names>W</given-names></name><name><surname>Belinky</surname><given-names>F</given-names></name><name><surname>Mohammed</surname><given-names>A</given-names></name><name><surname>Napierala</surname><given-names>M</given-names></name><name><surname>Usdin</surname><given-names>K</given-names></name><name><surname>Ansari</surname><given-names>AZ</given-names></name><name><surname>Mirkin</surname><given-names>SM</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Triplexes are Dynamic DNA Secondary Structures Formed in vivo and Linked to Genome Instability [END-seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203632">GSE203632</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to Agnel Sfeir, Amy LeBlanc, and Gianna Tricola for providing reagents. We thank the CCR Genomic Core for assisting with the NGS experiments performed in this study. We thank members of the Lazzerini Denchi laboratory, Sam John, Niek van Wietmarschen, and Travis Stracker for critical feedback on this work. This work utilized the computational resources of the NIH HPC Biowulf cluster (<ext-link ext-link-type="uri" xlink:href="https://hpc.nih.gov">https://hpc.nih.gov</ext-link>). Research in the ELD lab is funded by the NIH Intramural Research Program of the National Institutes of Health (NIH), National Cancer Institute (NCI), and Center for Cancer Research, project 1-ZIA-BC011815-03.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Wischnewski</surname><given-names>H</given-names></name><name><surname>Brun</surname><given-names>CM</given-names></name><name><surname>Schwarz</surname><given-names>T</given-names></name><name><surname>Azzalin</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5220</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6220</pub-id><pub-id pub-id-type="pmid">25330849</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azeroglu</surname><given-names>B</given-names></name><name><surname>Ozbun</surname><given-names>L</given-names></name><name><surname>Pegoraro</surname><given-names>G</given-names></name><name><surname>Lazzerini Denchi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Native FISH: A low- and high-throughput assay to analyze the alternative lengthening of telomere (ALT) pathway</article-title><source>Methods in Cell Biology</source><volume>182</volume><fpage>265</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/bs.mcb.2022.10.010</pub-id><pub-id pub-id-type="pmid">38359982</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azeroglu</surname><given-names>B</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Tricola</surname><given-names>GM</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Jubelin</surname><given-names>C</given-names></name><name><surname>Cortolezzis</surname><given-names>Y</given-names></name><name><surname>Pegoraro</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>KM</given-names></name><name><surname>Stracker</surname><given-names>TH</given-names></name><name><surname>Lazzerini Denchi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Identification of modulators of the ALT pathway through a native FISH-based optical screen</article-title><source>Cell Reports</source><volume>44</volume><elocation-id>115114</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.115114</pub-id><pub-id pub-id-type="pmid">39729394</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barefield</surname><given-names>C</given-names></name><name><surname>Karlseder</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The BLM helicase contributes to telomere maintenance through processing of late-replicating intermediate structures</article-title><source>Nucleic Acids Research</source><volume>40</volume><fpage>7358</fpage><lpage>7367</lpage><pub-id pub-id-type="doi">10.1093/nar/gks407</pub-id><pub-id pub-id-type="pmid">22576367</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barroso-González</surname><given-names>J</given-names></name><name><surname>García-Expósito</surname><given-names>L</given-names></name><name><surname>Hoang</surname><given-names>SM</given-names></name><name><surname>Lynskey</surname><given-names>ML</given-names></name><name><surname>Roncaioli</surname><given-names>JL</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>CT</given-names></name><name><surname>de Vitis</surname><given-names>M</given-names></name><name><surname>Modesti</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>KA</given-names></name><name><surname>Sarkar</surname><given-names>SN</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>O’Sullivan</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>RAD51AP1 is an essential mediator of alternative lengthening of telomeres</article-title><source>Molecular Cell</source><volume>79</volume><elocation-id>202006026</elocation-id><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.026</pub-id><pub-id pub-id-type="pmid">32679078</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Lynskey</surname><given-names>ML</given-names></name><name><surname>O’Sullivan</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>New twists to the ALTernative endings at telomeres</article-title><source>DNA Repair</source><volume>115</volume><elocation-id>103342</elocation-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2022.103342</pub-id><pub-id pub-id-type="pmid">35588569</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname><given-names>TM</given-names></name><name><surname>Englezou</surname><given-names>A</given-names></name><name><surname>Dalla-Pozza</surname><given-names>L</given-names></name><name><surname>Dunham</surname><given-names>MA</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines</article-title><source>Nature Medicine</source><volume>3</volume><fpage>1271</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.1038/nm1197-1271</pub-id><pub-id pub-id-type="pmid">9359704</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>SW</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>CST-Polα/Primase: the second telomere maintenance machine</article-title><source>Genes &amp; Development</source><volume>37</volume><fpage>555</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1101/gad.350479.123</pub-id><pub-id pub-id-type="pmid">37495394</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canela</surname><given-names>A</given-names></name><name><surname>Sridharan</surname><given-names>S</given-names></name><name><surname>Sciascia</surname><given-names>N</given-names></name><name><surname>Tubbs</surname><given-names>A</given-names></name><name><surname>Meltzer</surname><given-names>P</given-names></name><name><surname>Sleckman</surname><given-names>BP</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>DNA breaks and end resection measured genome-wide by end sequencing</article-title><source>Molecular Cell</source><volume>63</volume><fpage>898</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.06.034</pub-id><pub-id pub-id-type="pmid">27477910</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesare</surname><given-names>AJ</given-names></name><name><surname>Griffith</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Telomeric DNA in ALT cells is characterized by free telomeric circles and heterogeneous t-loops</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>9948</fpage><lpage>9957</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.22.9948-9957.2004</pub-id><pub-id pub-id-type="pmid">15509797</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>NW</given-names></name><name><surname>Dilley</surname><given-names>RL</given-names></name><name><surname>Lampson</surname><given-names>MA</given-names></name><name><surname>Greenberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interchromosomal homology searches drive directional ALT telomere movement and synapsis</article-title><source>Cell</source><volume>159</volume><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.030</pub-id><pub-id pub-id-type="pmid">25259924</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claude</surname><given-names>E</given-names></name><name><surname>Decottignies</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>60</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2020.01.002</pub-id><pub-id pub-id-type="pmid">32114293</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claude</surname><given-names>E</given-names></name><name><surname>de Lhoneux</surname><given-names>G</given-names></name><name><surname>Pierreux</surname><given-names>CE</given-names></name><name><surname>Marbaix</surname><given-names>E</given-names></name><name><surname>de Ville de Goyet</surname><given-names>M</given-names></name><name><surname>Boulanger</surname><given-names>C</given-names></name><name><surname>Van Damme</surname><given-names>A</given-names></name><name><surname>Brichard</surname><given-names>B</given-names></name><name><surname>Decottignies</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Detection of alternative lengthening of telomeres mechanism on tumor sections</article-title><source>Molecular Biomedicine</source><volume>2</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1186/s43556-021-00055-y</pub-id><pub-id pub-id-type="pmid">35006465</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conomos</surname><given-names>D</given-names></name><name><surname>Stutz</surname><given-names>MD</given-names></name><name><surname>Hills</surname><given-names>M</given-names></name><name><surname>Neumann</surname><given-names>AA</given-names></name><name><surname>Bryan</surname><given-names>TM</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Variant repeats are interspersed throughout the telomeres and recruit nuclear receptors in ALT cells</article-title><source>The Journal of Cell Biology</source><volume>199</volume><fpage>893</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1083/jcb.201207189</pub-id><pub-id pub-id-type="pmid">23229897</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denchi</surname><given-names>EL</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1</article-title><source>Nature</source><volume>448</volume><fpage>1068</fpage><lpage>1071</lpage><pub-id pub-id-type="doi">10.1038/nature06065</pub-id><pub-id pub-id-type="pmid">17687332</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilley</surname><given-names>RL</given-names></name><name><surname>Verma</surname><given-names>P</given-names></name><name><surname>Cho</surname><given-names>NW</given-names></name><name><surname>Winters</surname><given-names>HD</given-names></name><name><surname>Wondisford</surname><given-names>AR</given-names></name><name><surname>Greenberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Break-induced telomere synthesis underlies alternative telomere maintenance</article-title><source>Nature</source><volume>539</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature20099</pub-id><pub-id pub-id-type="pmid">27760120</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drosopoulos</surname><given-names>WC</given-names></name><name><surname>Kosiyatrakul</surname><given-names>ST</given-names></name><name><surname>Schildkraut</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>BLM helicase facilitates telomere replication during leading strand synthesis of telomeres</article-title><source>The Journal of Cell Biology</source><volume>210</volume><fpage>191</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1083/jcb.201410061</pub-id><pub-id pub-id-type="pmid">26195664</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunham</surname><given-names>MA</given-names></name><name><surname>Neumann</surname><given-names>AA</given-names></name><name><surname>Fasching</surname><given-names>CL</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Telomere maintenance by recombination in human cells</article-title><source>Nature Genetics</source><volume>26</volume><fpage>447</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1038/82586</pub-id><pub-id pub-id-type="pmid">11101843</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldser</surname><given-names>DM</given-names></name><name><surname>Greider</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Short telomeres limit tumor progression in vivo by inducing senescence</article-title><source>Cancer Cell</source><volume>11</volume><fpage>461</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2007.02.026</pub-id><pub-id pub-id-type="pmid">17433785</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>L</given-names></name><name><surname>Rademacher</surname><given-names>A</given-names></name><name><surname>Mücke</surname><given-names>N</given-names></name><name><surname>Tirier</surname><given-names>SM</given-names></name><name><surname>Koeleman</surname><given-names>E</given-names></name><name><surname>Knotz</surname><given-names>C</given-names></name><name><surname>Schumacher</surname><given-names>S</given-names></name><name><surname>Stainczyk</surname><given-names>SA</given-names></name><name><surname>Westermann</surname><given-names>F</given-names></name><name><surname>Fröhling</surname><given-names>S</given-names></name><name><surname>Chudasama</surname><given-names>P</given-names></name><name><surname>Rippe</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>ALT-FISH quantifies alternative lengthening of telomeres activity by imaging of single-stranded repeats</article-title><source>Nucleic Acids Research</source><volume>50</volume><elocation-id>e61</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkac113</pub-id><pub-id pub-id-type="pmid">35188570</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>RA</given-names></name><name><surname>Allsopp</surname><given-names>RC</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Morin</surname><given-names>GB</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation</article-title><source>Oncogene</source><volume>16</volume><fpage>1723</fpage><lpage>1730</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201933</pub-id><pub-id pub-id-type="pmid">9582020</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greider</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Telomere length regulation</article-title><source>Annual Review of Biochemistry</source><volume>65</volume><fpage>337</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1146/annurev.bi.65.070196.002005</pub-id><pub-id pub-id-type="pmid">8811183</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grudic</surname><given-names>A</given-names></name><name><surname>Jul-Larsen</surname><given-names>A</given-names></name><name><surname>Haring</surname><given-names>SJ</given-names></name><name><surname>Wold</surname><given-names>MS</given-names></name><name><surname>Lønning</surname><given-names>PE</given-names></name><name><surname>Bjerkvig</surname><given-names>R</given-names></name><name><surname>Bøe</surname><given-names>SO</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>7267</fpage><lpage>7278</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm738</pub-id><pub-id pub-id-type="pmid">17959650</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Jia</surname><given-names>S</given-names></name><name><surname>Takasugi</surname><given-names>T</given-names></name><name><surname>Tesmer</surname><given-names>VM</given-names></name><name><surname>Nandakumar</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Distinct functions of POT1 proteins contribute to the regulation of telomerase recruitment to telomeres</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>5514</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25799-7</pub-id><pub-id pub-id-type="pmid">34535663</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henson</surname><given-names>JD</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huschtscha</surname><given-names>LI</given-names></name><name><surname>Chang</surname><given-names>AC</given-names></name><name><surname>Au</surname><given-names>AYM</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity</article-title><source>Nature Biotechnology</source><volume>27</volume><fpage>1181</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1038/nbt.1587</pub-id><pub-id pub-id-type="pmid">19935656</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>Sfeir</surname><given-names>AJ</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end</article-title><source>The EMBO Journal</source><volume>24</volume><fpage>2667</fpage><lpage>2678</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600733</pub-id><pub-id pub-id-type="pmid">15973431</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>Daniels</surname><given-names>JP</given-names></name><name><surname>Takai</surname><given-names>H</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres</article-title><source>Cell</source><volume>126</volume><fpage>63</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.04.044</pub-id><pub-id pub-id-type="pmid">16839877</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name><name><surname>Greenberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>BLM helicase unwinds lagging strand substrates to assemble the ALT telomere damage response</article-title><source>Molecular Cell</source><volume>84</volume><fpage>1684</fpage><lpage>1698</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2024.03.011</pub-id><pub-id pub-id-type="pmid">38593805</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>N</given-names></name><name><surname>Wondisford</surname><given-names>AR</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Lynskey</surname><given-names>ML</given-names></name><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Barroso-González</surname><given-names>J</given-names></name><name><surname>García-Expósito</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Mellacheruvu</surname><given-names>D</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Modesti</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>KM</given-names></name><name><surname>Nesvizhskii</surname><given-names>AI</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name><name><surname>O’Sullivan</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>RAD51AP1 regulates ALT-HDR through chromatin-directed homeostasis of TERRA</article-title><source>Molecular Cell</source><volume>82</volume><fpage>4001</fpage><lpage>4017</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.09.025</pub-id><pub-id pub-id-type="pmid">36265488</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>NW</given-names></name><name><surname>Piatyszek</surname><given-names>MA</given-names></name><name><surname>Prowse</surname><given-names>KR</given-names></name><name><surname>Harley</surname><given-names>CB</given-names></name><name><surname>West</surname><given-names>MD</given-names></name><name><surname>Ho</surname><given-names>PL</given-names></name><name><surname>Coviello</surname><given-names>GM</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Weinrich</surname><given-names>SL</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>NW</given-names></name><name><surname>Piatyszek</surname><given-names>MA</given-names></name><name><surname>Prowse</surname><given-names>KR</given-names></name><name><surname>Harley</surname><given-names>CB</given-names></name><name><surname>West</surname><given-names>MD</given-names></name><name><surname>Ho</surname><given-names>PL</given-names></name><name><surname>Coviello</surname><given-names>GM</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Weinrich</surname><given-names>SL</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>NW</given-names></name><name><surname>Piatyszek</surname><given-names>MA</given-names></name><name><surname>Prowse</surname><given-names>KR</given-names></name><name><surname>Harley</surname><given-names>CB</given-names></name><name><surname>West</surname><given-names>MD</given-names></name><name><surname>Ho</surname><given-names>PL</given-names></name><name><surname>Coviello</surname><given-names>GM</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Weinrich</surname><given-names>SL</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Specific association of human telomerase activity with immortal cells and cancer</article-title><source>Science</source><volume>266</volume><fpage>2011</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1126/science.7605428</pub-id><pub-id pub-id-type="pmid">7605428</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>CJ</given-names></name><name><surname>Cech</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>22</volume><fpage>283</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/s41580-021-00328-y</pub-id><pub-id pub-id-type="pmid">33564154</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loe</surname><given-names>TK</given-names></name><name><surname>Li</surname><given-names>JSZ</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Azeroglu</surname><given-names>B</given-names></name><name><surname>Boddy</surname><given-names>MN</given-names></name><name><surname>Denchi</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Telomere length heterogeneity in ALT cells is maintained by PML-dependent localization of the BTR complex to telomeres</article-title><source>Genes &amp; Development</source><volume>34</volume><fpage>650</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1101/gad.333963.119</pub-id><pub-id pub-id-type="pmid">32217664</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loe</surname><given-names>TK</given-names></name><name><surname>Lazzerini Denchi</surname><given-names>E</given-names></name><name><surname>Tricola</surname><given-names>GM</given-names></name><name><surname>Azeroglu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>ALTercations at telomeres: stress, recombination and extrachromosomal affairs</article-title><source>Biochemical Society Transactions</source><volume>51</volume><fpage>1935</fpage><lpage>1946</lpage><pub-id pub-id-type="doi">10.1042/BST20230265</pub-id><pub-id pub-id-type="pmid">37767563</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>O’Rourke</surname><given-names>JJ</given-names></name><name><surname>Sobinoff</surname><given-names>AP</given-names></name><name><surname>Allen</surname><given-names>JAM</given-names></name><name><surname>Nelson</surname><given-names>CB</given-names></name><name><surname>Tomlinson</surname><given-names>CG</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name><name><surname>Deans</surname><given-names>AJ</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The FANCM-BLM-TOP3A-RMI complex suppresses alternative lengthening of telomeres (ALT)</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2252</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10180-6</pub-id><pub-id pub-id-type="pmid">31138797</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynskey</surname><given-names>ML</given-names></name><name><surname>Brown</surname><given-names>EE</given-names></name><name><surname>Bhargava</surname><given-names>R</given-names></name><name><surname>Wondisford</surname><given-names>AR</given-names></name><name><surname>Ouriou</surname><given-names>JB</given-names></name><name><surname>Freund</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>BA</given-names></name><name><surname>Lardo</surname><given-names>SM</given-names></name><name><surname>Schamus-Hayes</surname><given-names>S</given-names></name><name><surname>Hainer</surname><given-names>SJ</given-names></name><name><surname>O’Sullivan</surname><given-names>RJ</given-names></name><name><surname>Bowman</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>HIRA protects telomeres against R-loop-induced instability in ALT cancer cells</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>114964</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114964</pub-id><pub-id pub-id-type="pmid">39509271</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos-Rodrigues</surname><given-names>G</given-names></name><name><surname>van Wietmarschen</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Tripathi</surname><given-names>V</given-names></name><name><surname>Koussa</surname><given-names>NC</given-names></name><name><surname>Pavani</surname><given-names>R</given-names></name><name><surname>Nathan</surname><given-names>WJ</given-names></name><name><surname>Callen</surname><given-names>E</given-names></name><name><surname>Belinky</surname><given-names>F</given-names></name><name><surname>Mohammed</surname><given-names>A</given-names></name><name><surname>Napierala</surname><given-names>M</given-names></name><name><surname>Usdin</surname><given-names>K</given-names></name><name><surname>Ansari</surname><given-names>AZ</given-names></name><name><surname>Mirkin</surname><given-names>SM</given-names></name><name><surname>Nussenzweig</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>S1-END-seq reveals DNA secondary structures in human cells</article-title><source>Molecular Cell</source><volume>82</volume><fpage>3538</fpage><lpage>3552</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2022.08.007</pub-id><pub-id pub-id-type="pmid">36075220</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzucco</surname><given-names>G</given-names></name><name><surname>Huda</surname><given-names>A</given-names></name><name><surname>Galli</surname><given-names>M</given-names></name><name><surname>Piccini</surname><given-names>D</given-names></name><name><surname>Giannattasio</surname><given-names>M</given-names></name><name><surname>Pessina</surname><given-names>F</given-names></name><name><surname>Doksani</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Telomere damage induces internal loops that generate telomeric circles</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5297</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19139-4</pub-id><pub-id pub-id-type="pmid">33082350</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clustered telomeres in phase-separated nuclear condensates engage mitotic DNA synthesis through BLM and RAD52</article-title><source>Genes &amp; Development</source><volume>33</volume><fpage>814</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1101/gad.324905.119</pub-id><pub-id pub-id-type="pmid">31171703</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nurk</surname><given-names>S</given-names></name><name><surname>Koren</surname><given-names>S</given-names></name><name><surname>Rhie</surname><given-names>A</given-names></name><name><surname>Rautiainen</surname><given-names>M</given-names></name><name><surname>Bzikadze</surname><given-names>AV</given-names></name><name><surname>Mikheenko</surname><given-names>A</given-names></name><name><surname>Vollger</surname><given-names>MR</given-names></name><name><surname>Altemose</surname><given-names>N</given-names></name><name><surname>Uralsky</surname><given-names>L</given-names></name><name><surname>Gershman</surname><given-names>A</given-names></name><name><surname>Aganezov</surname><given-names>S</given-names></name><name><surname>Hoyt</surname><given-names>SJ</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Logsdon</surname><given-names>GA</given-names></name><name><surname>Alonge</surname><given-names>M</given-names></name><name><surname>Antonarakis</surname><given-names>SE</given-names></name><name><surname>Borchers</surname><given-names>M</given-names></name><name><surname>Bouffard</surname><given-names>GG</given-names></name><name><surname>Brooks</surname><given-names>SY</given-names></name><name><surname>Caldas</surname><given-names>GV</given-names></name><name><surname>Chen</surname><given-names>N-C</given-names></name><name><surname>Cheng</surname><given-names>H</given-names></name><name><surname>Chin</surname><given-names>C-S</given-names></name><name><surname>Chow</surname><given-names>W</given-names></name><name><surname>de Lima</surname><given-names>LG</given-names></name><name><surname>Dishuck</surname><given-names>PC</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Dvorkina</surname><given-names>T</given-names></name><name><surname>Fiddes</surname><given-names>IT</given-names></name><name><surname>Formenti</surname><given-names>G</given-names></name><name><surname>Fulton</surname><given-names>RS</given-names></name><name><surname>Fungtammasan</surname><given-names>A</given-names></name><name><surname>Garrison</surname><given-names>E</given-names></name><name><surname>Grady</surname><given-names>PGS</given-names></name><name><surname>Graves-Lindsay</surname><given-names>TA</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name><name><surname>Hansen</surname><given-names>NF</given-names></name><name><surname>Hartley</surname><given-names>GA</given-names></name><name><surname>Haukness</surname><given-names>M</given-names></name><name><surname>Howe</surname><given-names>K</given-names></name><name><surname>Hunkapiller</surname><given-names>MW</given-names></name><name><surname>Jain</surname><given-names>C</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name><name><surname>Jarvis</surname><given-names>ED</given-names></name><name><surname>Kerpedjiev</surname><given-names>P</given-names></name><name><surname>Kirsche</surname><given-names>M</given-names></name><name><surname>Kolmogorov</surname><given-names>M</given-names></name><name><surname>Korlach</surname><given-names>J</given-names></name><name><surname>Kremitzki</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Maduro</surname><given-names>VV</given-names></name><name><surname>Marschall</surname><given-names>T</given-names></name><name><surname>McCartney</surname><given-names>AM</given-names></name><name><surname>McDaniel</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>DE</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Myers</surname><given-names>EW</given-names></name><name><surname>Olson</surname><given-names>ND</given-names></name><name><surname>Paten</surname><given-names>B</given-names></name><name><surname>Peluso</surname><given-names>P</given-names></name><name><surname>Pevzner</surname><given-names>PA</given-names></name><name><surname>Porubsky</surname><given-names>D</given-names></name><name><surname>Potapova</surname><given-names>T</given-names></name><name><surname>Rogaev</surname><given-names>EI</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Schneider</surname><given-names>VA</given-names></name><name><surname>Sedlazeck</surname><given-names>FJ</given-names></name><name><surname>Shafin</surname><given-names>K</given-names></name><name><surname>Shew</surname><given-names>CJ</given-names></name><name><surname>Shumate</surname><given-names>A</given-names></name><name><surname>Sims</surname><given-names>Y</given-names></name><name><surname>Smit</surname><given-names>AFA</given-names></name><name><surname>Soto</surname><given-names>DC</given-names></name><name><surname>Sović</surname><given-names>I</given-names></name><name><surname>Storer</surname><given-names>JM</given-names></name><name><surname>Streets</surname><given-names>A</given-names></name><name><surname>Sullivan</surname><given-names>BA</given-names></name><name><surname>Thibaud-Nissen</surname><given-names>F</given-names></name><name><surname>Torrance</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name><name><surname>Walenz</surname><given-names>BP</given-names></name><name><surname>Wenger</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>JMD</given-names></name><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>SM</given-names></name><name><surname>Young</surname><given-names>AC</given-names></name><name><surname>Zarate</surname><given-names>S</given-names></name><name><surname>Surti</surname><given-names>U</given-names></name><name><surname>McCoy</surname><given-names>RC</given-names></name><name><surname>Dennis</surname><given-names>MY</given-names></name><name><surname>Alexandrov</surname><given-names>IA</given-names></name><name><surname>Gerton</surname><given-names>JL</given-names></name><name><surname>O’Neill</surname><given-names>RJ</given-names></name><name><surname>Timp</surname><given-names>W</given-names></name><name><surname>Zook</surname><given-names>JM</given-names></name><name><surname>Schatz</surname><given-names>MC</given-names></name><name><surname>Eichler</surname><given-names>EE</given-names></name><name><surname>Miga</surname><given-names>KH</given-names></name><name><surname>Phillippy</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The complete sequence of a human genome</article-title><source>Science</source><volume>376</volume><fpage>44</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1126/science.abj6987</pub-id><pub-id pub-id-type="pmid">35357919</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname><given-names>K</given-names></name><name><surname>Bartocci</surname><given-names>C</given-names></name><name><surname>Ouzounov</surname><given-names>I</given-names></name><name><surname>Diedrich</surname><given-names>JK</given-names></name><name><surname>Denchi</surname><given-names>EL</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A two-step mechanism for TRF2-mediated chromosome-end protection</article-title><source>Nature</source><volume>494</volume><fpage>502</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1038/nature11873</pub-id><pub-id pub-id-type="pmid">23389450</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Sullivan</surname><given-names>RJ</given-names></name><name><surname>Arnoult</surname><given-names>N</given-names></name><name><surname>Lackner</surname><given-names>DH</given-names></name><name><surname>Oganesian</surname><given-names>L</given-names></name><name><surname>Haggblom</surname><given-names>C</given-names></name><name><surname>Corpet</surname><given-names>A</given-names></name><name><surname>Almouzni</surname><given-names>G</given-names></name><name><surname>Karlseder</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>21</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2754</pub-id><pub-id pub-id-type="pmid">24413054</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>O’Sullivan</surname><given-names>RJ</given-names></name><name><surname>Greenberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2025">2025</year><source>Mechanisms of Alternative Lengthening of Telomeres</source><publisher-name>Cold Spring Harb Perspect Biol</publisher-name></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palm</surname><given-names>W</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>How shelterin protects mammalian telomeres</article-title><source>Annual Review of Genetics</source><volume>42</volume><fpage>301</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1146/annurev.genet.41.110306.130350</pub-id><pub-id pub-id-type="pmid">18680434</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Biju</surname><given-names>B</given-names></name><name><surname>Ahmed</surname><given-names>N</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Goldenberg</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Mohan</surname><given-names>N</given-names></name><name><surname>Klosek</surname><given-names>S</given-names></name><name><surname>Parsa</surname><given-names>K</given-names></name><name><surname>Guh</surname><given-names>CY</given-names></name><name><surname>Lu</surname><given-names>R</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name><name><surname>Chu</surname><given-names>HP</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>19110</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-55537-5</pub-id><pub-id pub-id-type="pmid">31836759</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panier</surname><given-names>S</given-names></name><name><surname>Maric</surname><given-names>M</given-names></name><name><surname>Hewitt</surname><given-names>G</given-names></name><name><surname>Mason-Osann</surname><given-names>E</given-names></name><name><surname>Gali</surname><given-names>H</given-names></name><name><surname>Dai</surname><given-names>A</given-names></name><name><surname>Labadorf</surname><given-names>A</given-names></name><name><surname>Guervilly</surname><given-names>JH</given-names></name><name><surname>Ruis</surname><given-names>P</given-names></name><name><surname>Segura-Bayona</surname><given-names>S</given-names></name><name><surname>Belan</surname><given-names>O</given-names></name><name><surname>Marzec</surname><given-names>P</given-names></name><name><surname>Gaillard</surname><given-names>PHL</given-names></name><name><surname>Flynn</surname><given-names>RL</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SLX4IP antagonizes promiscuous BLM activity during ALT maintenance</article-title><source>Molecular Cell</source><volume>76</volume><fpage>27</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.07.010</pub-id><pub-id pub-id-type="pmid">31447390</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perera</surname><given-names>SA</given-names></name><name><surname>Maser</surname><given-names>RS</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>McNamara</surname><given-names>K</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Kim</surname><given-names>CF</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Castrillon</surname><given-names>DH</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Depinho</surname><given-names>RA</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Telomere dysfunction promotes genome instability and metastatic potential in a K-ras p53 mouse model of lung cancer</article-title><source>Carcinogenesis</source><volume>29</volume><fpage>747</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgn050</pub-id><pub-id pub-id-type="pmid">18283039</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintanilla</surname><given-names>I</given-names></name><name><surname>Azeroglu</surname><given-names>B</given-names></name><name><surname>Sagar</surname><given-names>MAK</given-names></name><name><surname>Stracker</surname><given-names>TH</given-names></name><name><surname>Denchi</surname><given-names>EL</given-names></name><name><surname>Pegoraro</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Optical pooled screening for the discovery of regulators of the alternative lengthening of telomeres pathway</article-title><source>Methods</source><volume>241</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2025.05.001</pub-id><pub-id pub-id-type="pmid">40324704</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfeir</surname><given-names>AJ</given-names></name><name><surname>Chai</surname><given-names>W</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Wright</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Telomere-end processing the terminal nucleotides of human chromosomes</article-title><source>Molecular Cell</source><volume>18</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2005.02.035</pub-id><pub-id pub-id-type="pmid">15808515</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sfeir</surname><given-names>A</given-names></name><name><surname>Kosiyatrakul</surname><given-names>ST</given-names></name><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>MacRae</surname><given-names>SL</given-names></name><name><surname>Karlseder</surname><given-names>J</given-names></name><name><surname>Schildkraut</surname><given-names>CL</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication</article-title><source>Cell</source><volume>138</volume><fpage>90</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.06.021</pub-id><pub-id pub-id-type="pmid">19596237</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shay</surname><given-names>JW</given-names></name><name><surname>Bacchetti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>A survey of telomerase activity in human cancer</article-title><source>European Journal of Cancer</source><volume>33</volume><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(97)00062-2</pub-id><pub-id pub-id-type="pmid">9282118</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>B</given-names></name><name><surname>Pentz</surname><given-names>R</given-names></name><name><surname>Figueira</surname><given-names>AM</given-names></name><name><surname>Arora</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>YW</given-names></name><name><surname>Hodson</surname><given-names>C</given-names></name><name><surname>Wischnewski</surname><given-names>H</given-names></name><name><surname>Deans</surname><given-names>AJ</given-names></name><name><surname>Azzalin</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2253</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10179-z</pub-id><pub-id pub-id-type="pmid">31138795</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smoom</surname><given-names>R</given-names></name><name><surname>May</surname><given-names>CL</given-names></name><name><surname>Ortiz</surname><given-names>V</given-names></name><name><surname>Tigue</surname><given-names>M</given-names></name><name><surname>Kolev</surname><given-names>HM</given-names></name><name><surname>Rowe</surname><given-names>M</given-names></name><name><surname>Reizel</surname><given-names>Y</given-names></name><name><surname>Morgan</surname><given-names>A</given-names></name><name><surname>Egyes</surname><given-names>N</given-names></name><name><surname>Lichtental</surname><given-names>D</given-names></name><name><surname>Skordalakes</surname><given-names>E</given-names></name><name><surname>Kaestner</surname><given-names>KH</given-names></name><name><surname>Tzfati</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Telomouse-a mouse model with human-length telomeres generated by a single amino acid change in RTEL1</article-title><source>Nature Communications</source><volume>14</volume><elocation-id>6708</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-023-42534-6</pub-id><pub-id pub-id-type="pmid">37872177</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobinoff</surname><given-names>AP</given-names></name><name><surname>Allen</surname><given-names>JA</given-names></name><name><surname>Neumann</surname><given-names>AA</given-names></name><name><surname>Yang</surname><given-names>SF</given-names></name><name><surname>Walsh</surname><given-names>ME</given-names></name><name><surname>Henson</surname><given-names>JD</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name><name><surname>Pickett</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BLM and SLX4 play opposing roles in recombination-dependent replication at human telomeres</article-title><source>The EMBO Journal</source><volume>36</volume><fpage>2907</fpage><lpage>2919</lpage><pub-id pub-id-type="doi">10.15252/embj.201796889</pub-id><pub-id pub-id-type="pmid">28877996</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>KK</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Blackwood</surname><given-names>S</given-names></name><name><surname>Gandhi</surname><given-names>R</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>In vivo stoichiometry of shelterin components</article-title><source>The Journal of Biological Chemistry</source><volume>285</volume><fpage>1457</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.038026</pub-id><pub-id pub-id-type="pmid">19864690</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takai</surname><given-names>H</given-names></name><name><surname>Aria</surname><given-names>V</given-names></name><name><surname>Borges</surname><given-names>P</given-names></name><name><surname>Yeeles</surname><given-names>JTP</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>CST-polymerase α-primase solves a second telomere end-replication problem</article-title><source>Nature</source><volume>627</volume><fpage>664</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07137-1</pub-id><pub-id pub-id-type="pmid">38418884</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tesmer</surname><given-names>VM</given-names></name><name><surname>Brenner</surname><given-names>KA</given-names></name><name><surname>Nandakumar</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Human POT1 protects the telomeric ds-ss DNA junction by capping the 5’ end of the chromosome</article-title><source>Science</source><volume>381</volume><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1126/science.adi2436</pub-id><pub-id pub-id-type="pmid">37590346</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Multani</surname><given-names>AS</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Cosme-Blanco</surname><given-names>W</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>JM</given-names></name><name><surname>Bachilo</surname><given-names>O</given-names></name><name><surname>Pathak</surname><given-names>S</given-names></name><name><surname>Tahara</surname><given-names>H</given-names></name><name><surname>Bailey</surname><given-names>SM</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Behringer</surname><given-names>RR</given-names></name><name><surname>Chang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres</article-title><source>Cell</source><volume>126</volume><fpage>49</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.05.037</pub-id><pub-id pub-id-type="pmid">16839876</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Takai</surname><given-names>H</given-names></name><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Telomeric 3’ overhangs derive from resection by Exo1 and Apollo and fill-in by POT1b-associated CST</article-title><source>Cell</source><volume>150</volume><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.05.026</pub-id><pub-id pub-id-type="pmid">22748632</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106657.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cooper</surname><given-names>Julia Promisel</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Colorado Anschutz Medical Campus</institution><country>United States</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Fundamental</kwd></kwd-group></front-stub><body><p>This study demonstrates the application of END-seq, originally developed to study genomewide DNA double-strand breaks, to telomere biology; the work packs a punch, concisely demonstrating the utility of this approach and the new insights that can be gained. The authors confirm that telomeres in telomerase-positive cells terminate with 5'-ATC in a Pot1-dependent manner and demonstrate that this principle holds true in telomerase-negative ALT cells as well. S1-END-seq is similarly developed for telomeres, showing that ALT cells harbor several regions of ssDNA. The study is well-executed and <bold>convincing</bold>, the new insights are <bold>fundamental</bold> and <bold>compelling</bold>, and the optimized END-seq approaches will be widely utilized. The work will prompt additional studies that the reviewers look forward to, including combining telomeric END-seq with long-read sequencing to address the distribution and origin of variant telomere repeats and ssDNA along telomeres in ALT and telomerase-positive settings.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106657.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary</p><p>This manuscript from Azeroglu et al. presents the application of END-Seq to examine the sequence composition of chromosome termini, i.e., telomeres. END-seq is a powerful genome sequencing strategy developed in Andre Nussesweig's lab to examine the sequences at DNA break sites. Here, END-Seq is applied to explore the nucleotide sequences at telomeres and to ascertain (i) whether the terminal end sequence is conserved in cells that activate ALT telomere elongation mechanism and (ii) whether the processes responsible for telomere end sequence regulation are conserved. With these aims clearly articulated, the authors convincingly show the power of this technique to examine telomere end-processing.</p><p>Strengths</p><p>(1) The authors effectively demonstrate the application of END-seq for these purposes. They verify prior data that 5'terminal sequences of telomeres in Hela and RPE cells end in a canonical ATC sequence motif. They verify that the same sequence is present at the 5' ends of telomeres by performing END-seq across a panel of ALT cancer cells. As in non-ALT cells, the established role of POT1, a ssDNA telomere binding protein, in coordinating the mechanism that maintains the canonical ATC motif is likewise verified. However, by performing END-Seq in mouse cells lacking POT1 isoforms, POT1a and POT1b, the authors uncover that POT1b is dispensable for this process. This reveals a novel, important insight relating to the evolution of POT1 as a telomere regulatory factor.</p><p>(2) The authors then demonstrate the utility of S1-END-seq, a variation of END-Seq, to explore the purported abundance of single-stranded DNA at telomeres within telomeres of ALT cancer cells. Here, they demonstrate that ssDNA abundance is an intrinsic aspect of ALT telomeres and is dependent on the activity of BLM, a crucial mediator of ALT.</p><p>Overall, the authors have effectively shown that END-seq can be applied to examine processes maintaining telomeres in normal and cancerous cells across multiple species. Using END-Seq, the authors confirm prior cell biological and sequencing data and the role of POT1 and BLM in regulating telomere termini sequences and ssDNA abundance. The study is nice and well-written, with the experimental rationale and outcomes clearly explained.</p><p>Weaknesses</p><p>This reviewer finds little to argue with in this study. It is timely and highly valuable for the telomere field. One minor question would be whether the authors could expand more on the application of END-Seq to examine the processive steps of the ALT mechanism? Can they speculate if the ssDNA detected in ALT cells might be an intermediate generated during BIR (i.e., is the ssDNA displaced strand during BIR) or a lesion? Furthermore, have the authors assessed whether ssDNA lesions are due to the loss of ATRX or DAXX, either of which can be mutated in the ALT setting?</p><p>Comments on revisions:</p><p>The authors addressed the comments. Thank you.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106657.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This is a short yet very clear manuscript demonstrating that two methods (END-seq and S1-END-seq), previously developed in the Nussenzweig laboratory to study DSBs in the genome, can also be applied to the 5' ends of mammalian telomeres and the accumulation of telomeric single-stranded DNA.</p><p>The authors first validate the applicability of END-seq using different approaches and confirm that mammalian telomeres preferentially end with an ATC 5' end through a mechanism that requires intact POT1 (POT1a in mice). They then extend their analysis to cells that maintain telomeres through the ALT mechanism and demonstrate that, in these cells as well, telomeres frequently end in an ATC 5' sequence via a POT1-dependent mechanism. Using S1-END-seq, the authors further show that ALT telomeres contain single-stranded DNA and estimate that each telomere in ALT cells harbors at least five regions of ssDNA.</p><p>I find this work very interesting and incisive. It clearly demonstrates that END-seq can be applied with unprecedented depth and precision to the study of telomeric features such as the 5' end and ssDNA. The data are very clear and thoroughly interpreted, and the manuscript is well written. The results are carefully analyzed and effectively presented. Overall, I find this manuscript worthy of publication, as the optimized END-seq methods described here will likely be widely utilized in the telomere field.</p><p>Also, the authors have satisfactorily addressed my previous comments.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106657.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>A subset of cancer cells attain replicative immortality by activating the ALT mechanism of telomere maintenance, which is currently the subject of intense research due to its potential for novel targeted therapies. Key questions remain in the field, such as whether ALT telomeres adhere to the same end-protection rules as telomeres in telomerase-expressing cells, or if ALT telomeres possess unique properties that could be targeted with new, less toxic cancer therapies. Both questions, along with the approaches developed by the authors to address them, are highly relevant.</p><p>Strengths:</p><p>Since chromosome ends resemble one-ended DSBs, the authors hypothesized that the previously described END-SEQ protocol could be used to accurately sequence the 5' end of telomeres on the C-rich strand. As expected, most reads corresponded to the C-rich strand and, confirming previous observation by the de Lange's group, most chromosomes end with the ATC-5' sequence, a feature that was found to be dependent on POT1 and to be conserved in both human ALT cells and mouse cells. Through a complementary method, S1-END-SEQ, the authors further explored ssDNA regions at telomeres, providing new insights into the characteristics of ALT telomeres. The study is original, the experiments were well-controlled and excellently executed.</p><p>Weaknesses:</p><p>A few additional experiments would have strengthened the results such as combining error-free long-read sequencing with END-SEQ to compare the abundance of VTRs within telomeres versus at their distal ends.</p><p>Along this line, are VTRs increased at ssDNA regions of ALT telomeres? What is the frequency of VTRs in the END-SEQ analysis of TRF1-FokI-expressing ALT cells? Is it also increased? Has TRF1-FokI been applied to telomerase-expressing cells to compare VTR frequencies at internal sites between ALT and telomerase-expressing cells?</p><p>To what extent do ECTRs contribute to telomeric ssDNA?</p><p>Future experiments may help shed light on this</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.106657.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Azeroglu</surname><given-names>Benura</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Wei</given-names></name><role specific-use="author">Author</role><aff><institution>Shanghai Institute of Biochemistry and Cell Biology</institution><addr-line><named-content content-type="city">Shangai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Pavani</surname><given-names>Raphael</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sandhu</surname><given-names>Ranjodh Singh</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>Tadahiko</given-names></name><role specific-use="author">Author</role><aff><institution>Kyoto University</institution><addr-line><named-content content-type="city">Kyoto</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Nussenzweig</surname><given-names>Andre</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Lazzerini-Denchi</surname><given-names>Eros</given-names></name><role specific-use="author">Author</role><aff><institution>National Cancer Institute</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations for the authors):</bold></p><p>One minor question would be whether the authors could expand more on the application of END-Seq to examine the processive steps of the ALT mechanism? Can they speculate if the ssDNA detected in ALT cells might be an intermediate generated during BIR (i.e., is the ssDNA displaced strand during BIR) or a lesion? Furthermore, have the authors assessed whether ssDNA lesions are due to the loss of ATRX or DAXX, either of which can be mutated in the ALT setting?</p></disp-quote><p>We appreciate the reviewer’s insightful questions regarding the application of our assays to investigate the nature of the ssDNA detected in ALT telomeres. Our primary aim in this study was to establish the utility of END-seq and S1-END-seq in telomere biology and to demonstrate their applicability across both ALT-positive and -negative contexts. We agree that exploring the mechanistic origins of ssDNA would be highly informative, and we anticipate that END-seq–based approaches will be well suited for such future studies. However, it remains unclear whether the resolution of S1-END-seq is sufficient to capture transient intermediates such as those generated during BIR. We have now included a brief speculative statement in the revised discussion addressing the potential nature of ssDNA at telomeres in ALT cells.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations for the authors):</bold></p><p>How can we be sure that all telomeres are equally represented? The authors seem to assume that END-seq captures all chromosome ends equally, but can we be certain of this? While I do not see an obvious way to resolve this experimentally, I recommend discussing this potential bias more extensively in the manuscript.</p></disp-quote><p>We thank the reviewer for raising this important point. END-seq and S1-END-seq are unbiased methods designed to capture either double-stranded or single-stranded DNA that can be converted into blunt-ended double-stranded DNA and ligated to a capture oligo. As such, if a subset of telomeres cannot be processed using this approach, it is possible that these telomeres may be underrepresented or lost. However, to our knowledge, there are no proposed telomeric structures that would prevent capture using this method. For example, even if a subset of telomeres possesses a 5′ overhang, it would still be captured by END-seq. Indeed, we observed the consistent presence of the 5′-ATC motif across multiple cell lines and species (human, mouse, and dog). More importantly, we detected predictable and significant changes in sequence composition when telomere ends were experimentally altered, either in vivo (via POT1 depletion) or in vitro (via T7 exonuclease treatment). Together, these findings support the robustness of the method in capturing a representative and dynamic view of telomeres across different systems.</p><p>That said, we have now included a brief statement in the revised discussion acknowledging that we cannot fully exclude the possibility that a subset of telomeres may be missed due to unusual or uncharacterized structures</p><disp-quote content-type="editor-comment"><p>I believe Figures 1 and 2 should be merged.</p></disp-quote><p>We appreciate the reviewer’s suggestion to merge Figures 1 and 2. However, we feel that keeping them as separate figures better preserves the logical flow of the manuscript and allows the validation of END-seq and its application to be presented with appropriate clarity and focus. We hope the reviewer agrees that this layout enhances the clarity and interpretability of the data.</p><disp-quote content-type="editor-comment"><p>Scale bars should be added to all microscopy figures.</p></disp-quote><p>We thank the reviewer for pointing this out. We have now added scale bars to all the microscopy panels in the figures and included the scale details in the figure legends.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations for the authors):</bold></p><p>Overall, the discussion section is lacking depth and should be expanded and a few additional experiments should be performed to clarify the results.</p></disp-quote><p>We thank the reviewer for the suggestions. Based on this reviewer’s comments and comments for the other reviewers, we incorporated several points into the discussion. As a result, we hope that we provide additional depth to our conclusions.</p><disp-quote content-type="editor-comment"><p>(1) The finding that the abundance of variant telomeric repeats (VTRs) within the final 30 nucleotides of the telomeric 5' ends is similar in both telomerase-expressing and ALT cells is intriguing, but the authors do not address this result. Could the authors provide more insight into this observation and suggest potential explanations? As the frequency of VTRs does not seem to be upregulated in POT1-depleted cells, what then drives the appearance of VTRs on the C-strand at the very end of telomeres? Is CST-Pola complex responsible?</p></disp-quote><p>The reviewer raises a very interesting and relevant point. We are hesitant at this point to speculate on why we do not see a difference in variant repeats in ALT versus non-ALT cells, since additional data would be needed. One possibility is that variant repeats in ALT cells accumulate stochastically within telomeres but are selected against when they are present at the terminal portion of chromosome ends. However, to prove this hypothesis, we would need error-free long-read technology combined with END-seq. We feel that developing this approach would be beyond the scope of this manuscript.</p><disp-quote content-type="editor-comment"><p>(2) The authors also note that, in ALT cells, the frequency of VTRs in the first 30 nucleotides of the S1-END-SEQ reads is higher compared to END-SEQ, but this finding is not discussed either. Do the authors think that the presence of ssDNA regions is associated with the VTRs? Along this line, what is the frequency of VTRs in the END-SEQ analysis of TRF1-FokI-expressing ALT cells? Is it also increased? Has TRF1-FokI been applied to telomerase-expressing cells to compare VTR frequencies at internal sites between ALT and telomerase-expressing cells?</p></disp-quote><p>Similarly to what is discussed above, short reads have the advantage of being very accurate but do not provide sufficient length to establish the relative frequency of VTRs across the whole telomere sequence. The TRF1-FokI experiment is a good suggestion, but it would still be biased toward non-variant repeats due to the TRF1-binding properties. We plan to address these questions in a future study involving long-read sequencing and END-seq capture of telomeres.</p><disp-quote content-type="editor-comment"><p>Finally, in these experiments (S1-END-SEQ or END-SEQ in TRF1-Fok1), is the frequency of VTRs the same on both the C- and the G-rich strands? It is possible that the sequences are not fully complementary in regions where G4 structures form.</p></disp-quote><p>We thank the reviewer for this observation. While we do observe a higher frequency of variant telomeric repeats (VTRs) in the first 30 nucleotides of S1-END-seq reads compared to END-seq in ALT cells, we are currently unable to determine whether this difference is significant, as an appropriate control or matched normalization strategy for this comparison is lacking. Therefore, we refrain from overinterpreting the biological relevance of this observation.</p><p>The reviewer is absolutely correct. Our calculation did not exclude the possibility of extrachromosomal DNA as a source of telomeric ssDNA. We have now addressed this point in our discussion.</p><p>The reviewer is correct in pointing out that we still do not know what causes ssDNA at telomeres in ALT cells. Replication stress seems the most logical explanation based on the work of many labs in the field. However, our data did not reveal any significant difference in the levels of ssDNA at telomeres in non-ALT cells based on telomere length. We used the HeLa1.2.11 cell line (now clarified in the Materials section), which is the parental line of HeLa1.3 and has similarly long telomeres (~20 kb vs. ~23 kb). Despite their long telomeres and potential for replication-associated challenges such as G-quadruplex formation, HeLa1.2.11 cells did not exhibit the elevated levels of telomeric ssDNA that we observed in ALT cells (Figure 4B). Additional experiments are needed to map the occurrence of ssDNA at telomeres in relation to progression toward ALT.</p><disp-quote content-type="editor-comment"><p>(3) Based on the ratio of C-rich to G-rich reads in the S1-END-SEQ experiment, the authors estimate that ALT cells contain at least 3-5 ssDNA regions per chromosome end. While the calculation is understandable, this number could be discussed further to consider the possibility that the observed ratios (of roughly 0.5) might result from the presence of extrachromosomal DNA species, such as C-circles. The observed increase in the ratio of C-rich to G-rich reads in BLM-depleted cells supports this hypothesis, as BLM depletion suppresses C-circle formation in U2OS cells. To test this, the authors should examine the impact of POLD3 depletion on the C-rich/G-rich read ratio. Alternatively, they could separate high-molecular-weight (HMW) DNA from low-molecular-weight DNA in ALT cells and repeat the S1-END-SEQ in the HMW fraction.</p></disp-quote><p>The reviewer is absolutely correct. Our calculation did not exclude the possibility of extrachromosomal DNA as a source of telomeric ssDNA. We have now addressed this point in our discussion.</p><disp-quote content-type="editor-comment"><p>(4) What is the authors' perspective on the presence of ssDNA at ALT telomeres? Do they attribute this to replication stress? It would be helpful for the authors to repeat the S1-END-SEQ in telomerase-expressing cells with very long telomeres, such as HeLa1.3 cells, to determine if ssDNA is a specific feature of ALT cells or a result of replication stress. The increased abundance of G4 structures at telomeres in HeLa1.3 cells (as shown in J. Wong's lab) may indicate that replication stress is a factor. Similar to Wong's work, it would be valuable to compare the C-rich/G-rich read ratios in HeLa1.3 cells to those in ALT cells with similar telomeric DNA content.</p></disp-quote><p>The reviewer is correct in pointing out that we still do not know what causes ssDNA at telomeres in ALT cells. Replication stress seems the most logical explanation based on the work of many labs in the field. However, our data did not reveal any significant difference in the levels of ssDNA at telomeres in non-ALT cells based on telomere length. We used the HeLa1.2.11 cell line (now clarified in the Materials section), which is the parental line of HeLa1.3 and has similarly long telomeres (~20 kb vs. ~23 kb). Despite their long telomeres and potential for replication-associated challenges such as G-quadruplex formation, HeLa1.2.11 cells did not exhibit the elevated levels of telomeric ssDNA that we observed in ALT cells (Figure 4B). Additional experiments are needed to map the occurrence of ssDNA at telomeres in relation to progression toward ALT.</p><p>Finally, Reviewer #3 raises a list of minor points:</p><p>(1) The Y-axes of Figure 4 have been relabeled to account for the G-strand reads.</p><p>(2) Statistical analyses have been added to the figures where applicable.</p><p>(3) The manuscript has been carefully proofread to improve clarity and consistency throughout the text and figure legends</p><p>(4) We have revised the text to address issues related to the lack of cross-referencing between the supplementary figures and their corresponding legends.</p></body></sub-article></article>